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Thesis Abstract
In Chapter 1, site-specifically phosphorylated variants of the oncogene Akt1 were made in
Escherichia coli using the orthogonal translation system that enable genetic code expansion
with phosphoserine. The differentially phosphorylated variants of Akt1 were used to
validate newly predicted Akt1 substrates. The predicted target sites of the peptide
substrates were synthesized and subjected to in vitro kinase assays to quantify the activity
of each Akt1 phosphorylated variant towards the predicted peptide. A previously
uncharacterized kinase-substrate interaction between Akt1 and a peptide derived from
RAB11 Family Interacting Protein 2 (RAB11FIP2) was validated in vitro. Chapter 2
describes the preliminary development of a novel orthogonal translation system for
Bacillus subtilis. The work presented outlines the design process: from selection of the
components to the generation of an all-in-one plasmid containing the orthogonal translation
system. The work demonstrates stable integration of the orthogonal translation system into
the B. subtilis genome.

Keywords:
Genetic code expansion, Akt1, phosphoserine, phosphorylation, substrate specificity,
cancer, Bacillus subtilis, orthogonal translation system, synthetic biology, acetyllyisine
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Summary for Lay Audience
Nearly every living organism on the planet studied to date uses the same standard 20 amino
acid building blocks to create proteins and enzymes. Each of these 20 amino acids contains
a unique chemical functional group, including, for example, acidic/basic groups, aromatic
rings, sulfur groups, that each possess distinct chemical properties. Using different
combinations and sequences of these 20 building blocks, organisms can produce thousands
of different proteins with widely different functions.
Recent advances in genetics and molecular biology have led to the development of
technologies that can expand the repertoire of amino acids that are available for organisms
beyond these natural 20. The ability to expand the genetic code has led to 100’s of different
unnatural or non-standard amino acids being used by a wide range of organisms from
bacteria to mice. These new amino acids can revolutionize the types of proteins that
organisms can produce by providing them with chemical functional groups that were
previously not available. The work presented here makes use of such a system to produce
active variants of a human protein called Akt1 that is commonly overactivated in cancers.
These active Akt1 variants are made by introducing phosphorylation amino acids into the
Akt1 protein, leading to an active Akt1 enzyme. By testing these active variants, we
discovered a novel protein targets that Akt1 was able to act on. Results like these enhance
our understanding of the scope of Akt1’s role regulating pathways linked to cancer and
provide leads to investigate potential new drug targets. In the second chapter, I outline
pioneering efforts towards the creation of a novel genetic code expansion technology in a
species of bacteria (Bacillus subtilis) that did not previously have such a system. The design
process, starting with the careful selection of the components and eventual assembly into
a single plasmid DNA and integration into the B. subtilis genome is presented.
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CHAPTER 1 – Phospho-form specific substrates of protein kinase B (Akt1)

1.0 Abstract
Protein kinase B (Akt1) is hyper-activated in diverse human tumors. Akt1 is activated by
phosphorylation at two key regulatory sites, Thr308 and Ser473. Active Akt1
phosphorylates many, perhaps hundreds, of downstream cellular targets in the cytosol and
nucleus. Akt1 is well known for phosphorylating proteins that regulate cell survival and
apoptosis, however, the full catalog of Akt1 substrates remains unknown. Recent work
using large peptide libraries concludes that each active, phosphorylated form of Akt1
(pAkt1S473, pAkt1T308, ppAkt1S473,T308) has a distinct substrate specificity, and these data
were used to predict potential new Akt1 substrates. Using the most high-confidence
predictions, I designed 26 target peptides that represent putative Akt1 substrates. The
peptides, in addition to positive and negative control peptides, were synthesized by solid
phase synthesis and their purity was confirmed by mass spectrometry. I found that most of
the predicted peptides showed phosphorylation accepting activity equal to or greater than
that observed with a peptide derived from a well-established Akt1 substrate, glycogen
synthase kinase 3 β (GSK-3β). Some of the peptides displayed strong selectivity for either
the pAkt1S473 or the ppAkt1S473,T308 variant. The data support the hypothesis that Ser473
phosphorylation modulates Akt1 substrates selectivity. Akt1 was most active with putative
substrates including the PIP3-binding protein Rab11 family-interacting protein 2 and
cysteinyl leukotriene receptor 1, indicating their potential roles in Akt1-dependent cancers.

1.1 Introduction
1.1.1 Protein kinase B (Akt) is an oncogenic kinase.
Akt belongs to the AGC family of serine-threonine kinases (1,2). In mammals, there are
three Akt genes that encode the Akt isozymes Akt1, Akt2 and Akt3. The three isozymes
display high sequence identity, similar substrate specificity and share extensive homology
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in their kinase domains(1,2). All three Akt1 isozymes share the same fundamental structure
consisting of four distinct domains: an N-terminal regulatory pleckstin homology (PH)
domain; an unstructured linker region which serves to connect the PH domain to the
serine/threonine-specific kinase domain; and a final C-terminal domain often referred to as
the hydrophobic motif, which is responsible for discrete modifications to the activity of
Akt1(3). Akt1 is a key regulatory kinase that transduces signals through the
phosphoinositide 3-kinase (PI3K)/Akt1 cell-signaling cascade (1) that controls cell growth
and survival (2). The PI3K/Akt1 pathway is one of the most commonly deregulated
pathways in human cancer (4,5). In fact, Akt1 is hyper-phosphorylated and overactive in
>50% of human tumors (2,6,7), and elevated Akt1 phosphorylation status is linked to poor
prognosis in patients (5,8,9).

Figure 1.1: Growth factor mediated activation of Akt1. The activation pathway of Akt1
in response to growth factor mediated activation of the PI3K pathway is shown. Activated
Akt1 promotes an oncogenic cellular phenotype that exhibits inhibited autophagy and
apoptosis pathways and activated cellular growth, proliferation and anabolic pathways.
Akt1 inhibits autophagy via the TSC complex/mTORC1 pathway (10), and inhibits
apoptosis/promotes cellular growth through the inhibition of the tumour suppressors
FOXO and GSK-3β (11,12).
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1.1.2 Akt1 activation.
Activation of Akt1 is a multi-step process that involves a carefully orchestrated series
cellular translocation (13) and post translational modification events (reviewed in (2)).
Indeed, serine/threonine phosphorylation (14-16), methylation(17,18), ubiquitination (1921) and proline hydroxylation (22) have been shown to regulate the activation or to modify
the enzymatic activity of Akt1. Among these post translational modifications,
serine/threonine phosphorylation has been studied most extensively (1,2). Phosphorylation
of the threonine residue at position 308 (T308) in the activation loop of Akt1 is both
necessary and sufficient to achieve substantial Akt1 activity (15), however, a second
phosphorylation of the serine residue at position 473 (S473) in the C-terminal hydrophobic
motif of Akt1 is necessary to achieve maximal Akt1 catalytic activity (15).
In cells, the phosphorylation of Akt1 at positions T308 and S473 results from
insulin or growth factor stimulation of receptor tyrosine kinases and G protein coupled
receptors on the cell surface (23). Growth factor stimulation promotes plasma membrane
recruitment and subsequent activation of members of the class I PI3K family (Figure 1.1).
Following activation by receptor kinases, PI3K phosphorylates phosphatidylinositol-4,5bisphosphate (PIP2), converting PIP2 into phosphatidylinositol-3,4,5-triphosphate (PIP3)
(2). PIP3 acts a scaffold and forms an interaction with the PH domains of various proteins,
including Akt1 and phosphoinositide dependent kinase 1 (PDK1), another member of the
AGC kinase family which functions as the upstream kinase responsible for the activation
of Akt1. The interaction between PIP3 and the Akt1 PH domain causes Akt1 to adopt a
“PH-out” conformation, relieving Akt1 of the auto-inhibitory affect of its own PH domain
(24). The “PH-out” conformation of Akt1, along with its proximity to PDK1 mediated by
their interactions with PIP3 allows PDK1 to activate Akt1 by phosphorylation at Thr308
(25,26). Further activation is achieved after Akt1 is phosphorylated at Ser473 by the
mechanistic target of rapamycin complex 2 (mTORC2) (27). This mTORC2-mediated
phosphorylation of Akt1 at S473 is itself dependant on the contribution and activity of
numerous proteins (Protor (28), Sin1 (29), TSC2 (30), reviewed in (31)) which function to
stabilize mTORC2. Akt1 activity is normally down regulated (32) through deactivation via
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de-phosphorylation of Akt1 at Thr308 by protein phosphatase 2A (PP2A) (33) and at
Ser473 by PH domain leucine-rich repeat protein phosphatases (PHLPP) (34).

1.1.3 Therapeutic relevance of Akt1.
The Akt1 signaling pathway is a useful prognostic marker of various cancers as well as a
promising target for therapies (6-9). As of this report, the Akt1 pathway has been the
subject of over 300 clinical trials (35,36). The majority of these clinical trials investigate
small molecule inhibitors (37) as potential tools which can be used to inhibit or reduce the
activity of the hyper-active Akt1. Unfortunately, Akt1’s structural and functional similarity
to its isozymes and other members of the AGC-kinase family has made it difficult to solely
target Akt1 without also inhibiting additional kinases and causing unwanted side effects in
clinical trials (38).

1.1.4 The Akt1 signalling network.
Ultimately, the cellular consequences of Akt1 activity are determined by the profile of
substrates that it either activates or deactivates via phosphorylation in any given cellular
event (2). In order to identify new therapeutic targets for Akt1-dependent cancers, it is
important to identify the complete catalog of Akt1-dependent substrates. By expanding the
scope of pathways regulated by Akt1, new routes will emerge to inhibit specific
interactions between Akt1 and downstream substrates. Some Akt1 substrates are causative
agents in pathologies such as cancers (39) or diabetes (40). For example, in a study
investigating the rat model of the proapoptotic protein Par-4, it was found that Akt1 was
directly responsible for the inactivating phosphorylation of Par-4 (at that lead to oncogenic
inhibition of apoptosis (41).
As of 2019, Akt1 has over 200 reported substrates (1,2) that are involved in a wide
variety of cellular events, including signal transduction, metabolism, cell-cycle regulation,
transcription regulation, proliferation and angiogenesis (1,2). The level of certainty that all
of these substrates are bona fide Akt1 targets is substantiated by differing levels of
evidence. All substrates adhere to some degree to the Akt1 phosphorylation motif.
Pioneering efforts with peptide arrays defined the consensus Akt1 target motif as R-5X-4R-
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3X-2X-1S/T0ϕ1,

where X represents any amino acid, ϕ represents any bulky aromatic residue

and subscript numbers refer to the residue’s position relative to the phosphorylated residue
S or T (42). As reviewed in (1), many of the now “known” Akt1 substrates were originally
validated by in vitro kinases assays, including well-established Akt1 targets FOXO1A (43),
GSK-3β (44), WNK1 (45). Traditionally, in vivo studies using mouse models are used to
further validate reported Akt1 substrates. Homozygous knock-in mouse strains that either
lack PDK1 expression, PDK1(−/−) (46), or that express a PDK1 variant that is unable to
activate Akt1, which is catalytically active but unable to associate with PIP3/Akt1 (47),
have been used in combination to demonstrate the ability of Akt1 to phosphorylate
PRAS40, Foxo1, Foxo3, GSK-3β, TSC2 and WNK1 (47).

1.1.5 Investigating Akt1 substrate-specificity using genetic code expansion.
Recently, we developed a protocol that allows recombinant production of Akt1 variants
that are phosphorylated at either or both regulatory sites (Thr308, Ser473) (15) (Figure
1.2). To produce recombinant Akt1 that is phosphorylated at S473, an orthogonal
translation system (OTS) is used to reassign the UAG stop codon to genetically encode
phosphoserine (pSer). In general, an OTS requires two key components: an orthogonal
aminoacyl-tRNA synthetase (o-aaRS) and cognate orthogonal transfer RNA (o-tRNA)
pair. In an OTS, the aaRS charges its cognate tRNA with an unnatural amino acid (uAA)
that is usually provided to E. coli via direct supplementation of the growth media (Figure
1.1). Orthogonality in this case refers to the fact that the components of an OTS do not
possess the ability to cross-react with the host organism’s endogenous aaRSs and tRNAs.
In E. coli, the process of mRNA translation or protein synthesis involves over 100
discrete components, all of which must work efficiently to maintain protein synthesis and
production rates, which are essential to normal cell growth (48). To expand the natural
translation system, it is important that the engineered system does not interfere with or
compromise the integrity of the natural components. The orthogonal aaRS must only
recognize and aminoacylate its cognate orthogonal tRNA with a specific or desired
unnatural amino acid. Orthogonality ensures that the engineered aaRS does not charge any
of the endogenous E. coli tRNAs with the uAA so that the uAA is not incorporated
randomly throughout the proteome. Likewise, the orthogonal tRNA must not be charged
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with naturally occurring amino acids by any of the endogenous aaRSs present in E. coli so
that the OTS does not needlessly incorporate one of the naturally occurring amino acids in
place of an uAA at the UAG codon.
The pSer OTS used here (Figure 1.2A) was comprised of a phosphoseryl-tRNA
synthetase (SepRS) that was derived from an archaeal pathway for Cys-tRNACys
synthesis(49), a mutant tRNASep (50), and a mutant elongation factor-Tu (EF-Sep) (49).
During the development of the pSer OTS, it was determined that the inclusion of EF-Sep
was necessary to circumvent the quality-control functional of elongation factor-Tu, which
had prevented robust pSer incorporation in initial experiments with the pSer OTS (49).
Using the pSer OTS, we are able to reassign the UAG codon to genetically encode
pSer in response to a UAG codon at position 473 in the Akt1 construct (Figure 1.2 C and
D). Our lab has previously validated this method using multiple-reaction monitoring
MS/MS to unambiguously identify pSer at position 473 in Akt1 produced via this method
with no evidence of dephosphorylation. In order to produce recombinant Akt1 that is
phosphorylated at Thr308, the Akt1-upstream kinase PDK1 is co-expressed with Akt1. We
have previously demonstrated using parallel reaction-monitoring MS/MS that coexpression of PDK1 with Akt1 results in undetectable levels of unphosphorylated Thr308
in the purified pAkt1T308 product (15).
This method of Akt1 production has provided the unique opportunity to investigate
the substrate specificity of individual Akt1 phosphorylated forms in a manner that was not
previously possible (14). Compared to commercially available preparations of Akt1
produced using Sf9 insect cell lines that are of variable activity and contain mixtures of the
active Akt1 phospho-forms (15,51), our protocol is able to produce consistent preparations
of each individual phospho-form (15,16). Using these reagents, we defined the specific role
that each phosphorylation has on Akt1 activation (15) and inhibition by clinically relevant
compounds (16). We further showed that Akt1 phosphorylation status globally regulates
substrate specificity (14).
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Figure 1.2 Production of differentially phosphorylated Akt1 variants. A) (1) pDSpSer2 contains the phosphoserine orthogonal translation system (OTS) which was used to
genetically incorporate phosphoserine at position 473 in response to a UAG nonsense
codon in Akt1 mRNA transcripts. Plasmids (2-4) contain the Akt1 genes used to express
Akt1. Plasmid (2) contains Akt1 (without a TAG mutation at S473) and PDK1. Plasmid
(3) contains Akt1 with a TAG mutation at S473. Plasmid (4) contains both a mutated Akt1
gene (TAG at S473) and PDK1. In all, three different phospho-forms of Akt1 were
produced in E. coli: B) (mono-phosphorylated) pAkt1T308, C) (mono-phosphorylated)
pAkt1S473, and D) (dual-phosphorylated) ppAkt1T308/S473. B) To create pAkt1T308, E. coli
was transformed with (2) pCDF-Duet1-∆PHAkt1-PDK1 containing PDK1 (Akt1’s natural
upstream kinase) which is co-expressed along with Akt1 in order to phosphorylate T308.
C) To create pAkt1S473, E. coli was co-transformed with (1) pDS-pSer2 containing the OTS
which incorporates phosphoserine into Akt1 during translation in response to TAG codons
and (3) pCDF-Duet1-∆PHAkt1-473TAG which contains an Akt1 gene bearing a TAG
mutation at position S473. D) ppAkt1T308,S473 was created by combining both methods and
co-transforming E. coli with (1) pDS-pSer2 and (4) pCDF-Duet1-∆PHAkt1-473TAGPDK1. For the production of pAkt1S473 and ppAkt1T308,S473, E. coli were supplemented (2.5
mM) with pSer.
To study the substrate-specificities of individual Akt1 phospho-forms, our previous
efforts (14) tested an oriented peptide array library (OPAL) which contained over 6.9
billion unique, potential Akt1 substrates. The potential substrates in the OPAL screen were
partially degenerate peptides that had the following composition: Biotin-AGG-X-6X-5X-4R3X-2X-1S0X1X2X3A;

X represents any amino acid other than Ser, Thr or Cys. The OPAL

screen was subjected to kinase assays using radiolabeled ATP catalyzed by each of the
Akt1 phospho-forms. Data from the OPAL screen revealed that each phospho-form has
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distinct preferences for specific residues at each of the degenerate positions. This is a
standard method used to define the consensus substrate motif for a given kinase (42,52),
but the approach was not previously used to differentiate the substrate specificity of distinct
Akt1 phospho-forms. The results of the OPAL screens showed that each of the Akt1
phospho-forms had a distinct substrate specificity profile (14), demonstrating Akt1
substrate specificity is regulated by its phosphorylation status.
Here, peptides representing predicted Akt1 substrates based on the OPAL data were
synthesized and characterized for activity with each Akt1 phospho-form. For each of the
Akt1 phospho-forms, we were previously (14) able to determine the amino acids that were
either preferred or dis-favoured according to enzyme activity at each of the degenerate (X)
sites that surrounded the substrate’s phosphorylatable residue (S 0) in the consensus motif.
The OPAL data were used to create position-specific scoring matrices (PSSMs) for each
Akt1 phospho-form that quantify residues preferences at each site in the consensus motif.
The PSSMs where then used to search and rank the human phospho-proteome (14).
Using the PSSM scoring, we could then predict the expectation that a given known
phospho-peptide sequences was a likely substrate for one or more of the Akt1 phosphoforms. In order to validate substrates predicted by the OPAL data, I synthesized 26 potential
peptide substrates (Table 1.1) that represent novel putative Akt1 protein (1,2). The targeted
set of 30 peptides included those ranked highest (top 1%; p-value < 10-6) in our OPALderived PSSM search of the human phospho-proteome (14). The peptides were divided
into three sets, with each set representing peptides that were ranked highest for each of the
three phospho-forms. Kinase activity assays showed that the majority of putative substrates
displayed significant activity with at least one Akt1 phospho-form. Further the data
revealed novel and phospho-form-specific Akt1 substrates.
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Table 1.1. List of synthetic peptides representing predicted Akt1 substrates
gene

p-site

protein name

peptide sequence

MW
calc
(Da)

pAkt1S473
TWKRLRSHSRQYV 1717.0
HRH1
S396
histamine H1 receptor
FMQRLHSYWTLKR 1766.2
BRPF1
S542
peregrin
TSKRALSTWGPVP 1399.7
KIAA1109 S4592
uncharacterized protein
QWKRYSSKSWKRF 1787.2
TMC7
S125
transmembrane channel-like protein 7
KRVRSSSFTFHIT 1565.9
RANBP3L S77
Ran-binding protein 3-like
THQRVHTGTRPYM 1583.7
ZNF256
T374
zinc finger protein 256
PRKRLKSKGSDKD 1515.0
SKP2
S72
S-phase kinase-associated protein 2
YSKRTMTGYWSTQ 1608.9
LPHN3
T816
adhesion G protein-coupled receptor L3
EIQRLDTFSYSTN 1573.8
CMTM4
T208
MARVEL transmembrane 4
PRKRSDSSTYELD 1553.8
PITPNM2 S668
phosphatidylinositol transfer protein 2
pAkt1T308
FRKRLSTFRKHSL 1676.2
CYSLTR1 T308
cysteinyl leukotriene receptor 1
LRRRRRTFNRTAE 1732.1
GRAMD1C T515
GRAM domain containing 1C
QRKRKLSFRRRTD 1747.2
KCNH2
S890
potassium channel H2
RRHRISSFRPVED 1654.9
CDCA7L
S321
cell division cycle-associated 7-like
DRRRSNTLDIMDG 1548.9
FRYL
T1959
protein furry homolog-like
QKKRRHSFEHVSL 1651.9
ASH1L
S1226
histone-lysine N-methyltransferase
SRRM4
S125 serine/arginine repetitive matrix protein 4 KRRRSSSYSPSPV 1506.8
RKRRSSSYHVSMD 1608.9
SCN2A
S687
sodium channel protein type 2 alpha
YRRRHCSRRRLHR 1852.2
PRM2
S59
protamine-2
GRRRKYSLGRASR 1563.1
SEMA4G
S713
semaphorin-4G
ppAkt1T308,S473
QRKRKLSFRRRTD 1747.2
KCNH2
S890
potassium channel H2
FRKRLSTFRKHSL 1676.2
CYSLTR1 T308
cysteinyl leukotriene receptor 1
LRRRRRTFNRTAE 1732.1
GRAMD1C T515
GRAM domain containing 1C
SHGRTCSFGGFDL 1383.7
SASH1
S407
SAM and SH3 domain-containing
PHRRTLSFDTSKM 1575.9
RAB11FIP2 S277
Rab11 family-interacting protein 2
THARVLSMDGAGG 1271.6
PCNXL3
S505
pecanex-like 3
FHTRFRSMLRNVL 1677.1
FMO2
S241
dimethylaniline monooxygenase
QKKRRHSFEHVSL 1651.9
ASH1L
S1226
histone-lysine N-methyltransferase
MHSRHNSFDTVNT 1545.6
BTBD11
S65
ankyrin repeat and BTB/POZ
FRSRLDSYVRSLP 1596.0
TRAPPC1 S132
trafficking protein particle complex 1
Known substrate
SGRPRTTAFAESCKP 1522.7
GSK3B S9A N/A
Glycogen synthase kinase-3β (S9A)
SGRPRTTSFAESCKP 1538.7
GSK3B
S9
Glycogen synthase kinase-3β

MW PSSM
obs search
(Da) p-value
1716.0 4.6×10-7
1765.0 8.2×10-7
1398.8 1.6×10-6
1786.0 1.6×10-6
1564.9 3.1×10-6
1582.8 3.3×10-6
1514.0 3.4×10-6
1607.8 3.7×10-6
N/A 3.9×10-6
N/A 5.2×10-6
1675.1 1.8×10-7
1731.1 5.5×10-7
1746.2 1.4×10-6
1654.0 1.7×10-6
1547.8 1.8×10-6
1651.0 1.9×10-6
1505.9 2.6×10-6
1607.9 2.6×10-6
N/A 3.3×10-6
N/A 3.4×10-6
1729.1 7.3×10-7
1675.1 7.3×10-7
1731.0 1.1×10-6
1382.7 3.1×10-6
1574.9 4.4×10-6
1270.7 5.0×10-6
1676.0 5.1×10-6
1651.0 5.4×10-6
N/A 5.7×10-6
N/A 5.9×10-6
N/A
N/A
N/A 1.1×10-4

The ~18 Da discrepancy between the theoretical (1747.2 Da) and observed (1729.1 Da)
masses of the ppAkt1T308,S473 peptide QRKRKLSFRRRTD can be explained by a
phenomenon called mass-spec ionization induced thermal decomposition (TD) (53). TD
can result in the dehydration (mass – 18 Da) of peptide molecules in cases where the
peptide contains a C-terminal aspartic acid as is the case here. Due to limitations in the
capacity of samples that could be analyzed by the AB Sciex 5800 TOF/TOF System, the
potential peptide substrates corresponding to CMTM4, PITPNM2, PRM2, SEMA4G,
BTBD11, TRAPPC1, GSK3B and GSK3B(S9A) were not analyzed.
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1.2 Materials and Methods

1.2.1 Plasmids and bacterial strains.
Previously, our lab designed two expression plasmids capable of producing differentially
phosphorylated forms of recombinant human Akt1 from E. coli. Briefly, the first
expression plasmid contained a codon-optimized, PH domain–deficient, 6xHis-tagged
human AKT1 gene (residues 109-472, 45 kDa) (∆PH-AKT1), which was synthesized by
ATUM (Newark, CA, USA). The Akt1 gene was subcloned into an isopropyl β-D-1thiogalactopyranoside (IPTG)–inducible T7lac promoter–driven pCDF-Duet1 vector with
CloDF13-derived CDF replicon and streptomycin/spectinomycin resistance (pCDF-Duet1∆PH-Akt1) (15,16). In the absence of the genetic code expansion system (see below) the
pCDF-Duet1-∆PH-Akt1 vector causes E. coli to express an unphosphorylated and inactive
Akt1. The PDK1 gene was cloned at the second multi-cloning site (MSC2) (NdeI/KpnI) in
pCDF-Duet1-∆PHAkt1 to create the second expression plasmid: pCDF-Duet1-∆PHAkt1PDK1. The human PDK1 was purchased from the Harvard PlasmidID repository service
(plasmid ID: HsCD00001584; Boston, MA, USA).
In the absence of the genetic code expansion system (Figure 1.2), expression of the
pCDF-Duet1-∆PHAkt1-PDK1 vector in E. coli leads to production of a monophosphorylated Akt1 (pAkt1T308). The genetic code expansion system for phosphoserine
(pSer) is encoded on the pDS-pSer2 plasmid (15,54,55), which contains 5 copies of
tRNASep (56), phosphoseryl-tRNA synthetase (SepRS9), and elongation factor-Tu mutant
(EFSep21) (57).
Incorporation of pSer also required site-directed mutagenesis of the Ser473 codon
to TAG in the pCDF-Duet1-∆PHAkt1 and pCDF-Duet1-∆PHAkt1-PDK1 constructs to
generate the following constructs (16): pCDF-Duet1-∆PHAkt1-473TAG and pCDFDuet1-∆PHAkt1-PDK1-473TAG which produce the mono-phosphorylated Akt1 phosphoform (pAkt1S473) and dual-phosphorylated (ppAkt1T308,S473) Akt1 phospho-forms,
respectively. DNA sequencing services from the London Regional Genomics Centre
(London, ON, Canada) and Genewiz (Cambridge, MA, USA) were used to verify the
sequences of all cloned plasmids.
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1.2.2 Protein production in E. coli.
E. coli strain BL21(DE3) (ThermoFisher Scientific, Waltham, MA, USA) was used to
express all Akt1 protein variants (Figure 1.2). The pDS-pSer2 plasmid (54) was used to
incorporate pSer in response to a UAG codon at position 473 of ∆PHAkt1 in pCDF-Duet1∆PHAkt1 or pCDF-Duet1-∆PHAkt1-PDK1.
To produce un-phosphorylated Akt1, pCDF-Duet1-∆PHAkt1 (containing ∆PHAkt1
at MCS 1) was transformed into E. coli BL21(DE3) and plated on LB agar plates with 50
µg/ml streptomycin. To produce pAkt1T308, pCDF-Duet1-∆PHAkt1-PDK1 (containing
∆PHAkt1 at MCS 1 and PDK1 at MCS 2) was transformed into E. coli BL21(DE3) and
plated on LB agar plates with 50 µg/ml streptomycin. To produce pAkt1 S473 and
ppAkt1T308,S473, pCDF-Duet1-∆PHAkt1-473TAG or pCDF-Duet1-∆PHAkt1-473TAGPDK1, respectively, was co-transformed with pDS-pSer2 into E. coli Bl21(DE3) and
plated on LB (LB) agar plates with 25 µg/ml kanamycin and 50 µg/ml streptomycin. A
schematic representation of the production of each Akt1 phospho-form is shown in Figure
1.2. In all cases, a single colony was used to inoculate 50 ml of LB (with 50 µg/ml
streptomycin and, if needed, 25 µg/ml kanamycin), which was grown, shaking, overnight
at 37ºC. From this starter culture, a 10 ml inoculum was added to 1 l of LB with antibiotics
(as above) and, for pSer473-containing variants only, O-phospho-L-serine (Sigma Aldrich,
Oakville, ON, Canada) was added to a final concentration of 2.5 mM. The cultures were
grown at 37ºC until OD600 = 0.6, at which point, for pSer473-containing variants only, 2.5
mM of additional pSer was added to the culture. Protein expression was induced by adding
300 µM of IPTG at OD600 = 0.8. Cultures were then incubated at 16ºC for 18 h. Cells were
grown and pelleted at 5000 × g and stored at -80ºC until further analysis.

1.2.3 Protein production and purification.
Nickel (Ni+) affinity column chromatography was used to purify the 6xHis-tagged Akt1
variants. E. coli cell pellets containing recombinant Akt1 variants were resuspended in lysis
buffer (20 mM HEPES pH 7.0, 150 mM NaCl, 3 mM 2.2) β-mercaptoethanol, 3 mM DTT,
10 mM imidazole, 1 mM Na3VO4, 5 mM NaF, one cOmplete mini tablet (EDTA-free
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protease inhibitor mixture, Roche Applied Science, Millipore Sigma ID: 11697498001)
and 1 mM phenylmethylsulfonyl fluoride were added to the cell suspension at 10 ml/g of
cell pellet. Resuspended cell pellets were treated with lysozyme (1 mg/ml) for 20 min,
shaking at 4°C, and subsequently lysed using a French pressure cell press (American
Instrument Co. Inc.) at 1000 psi.
Cell lysates were centrifuged at 38,000 × g for 1 h at 4°C. The supernatant was
collected and filtered through a 1.2 μm filter, then mixed with 0.5 ml of Ni-nitrilotriacetic
acid (Ni-NTA) resin (Thermo-Fisher Scientific). Prior to the addition of the Ni-NTA resin
to the cell lysate supernatant, the resin was pre-equilibrated with lysis buffer for 1 hr. The
Ni-NTA resin-supernatant mixture was shaken gently on a rocker at 4ºC for 1 hr to allow
the resin to bind to the 6xHis-tagged Akt1.
The Ni-NTA resin-supernatant mixture was loaded into the Ni affinity column and
washed thoroughly first with 200 ml of wash buffer A (20 mM HEPES pH 7.0, 150 mM
NaCl, 3 mM β-mercaptoethanol, 3 mM Dithiothreitol, 1 mM Na3VO4, 5mM NaF and 15
mM imidazole), followed by 100 ml of wash buffer B (20 mM HEPES pH 7.0, 150 mM
NaCl, 3 mM β-mercaptoethanol, 3mM DTT, 1 mM Na3VO4, mM NaF and 20 mM
imidazole). The 6xHis-tagged Akt1 proteins were then eluted by washing the Ni-NTA resin
with 25 ml of elution buffer (20 mM HEPES pH 7.0, 150 mM NaCl, 3 mM βmercaptoethanol, 3mM dithiothreitol, 1 mM Na3VO4, 5 mM NaF and 100 mM imidazole).
The elution samples were then added to dialysis tubing (Sigma Aldrich, D6191) and
dialysed overnight in 2 L of imidazole-free lysis buffer to remove excess imidazole.
Finally, the Akt1-containing elution samples were concentrated down to ~1 ml using Pierce
Protein concentration PES centrifuge tubes with 30K MWCO (Thermo Scientific, 88529)
and protein concentration of each sample was determined using a Bradford assay.

1.2.4 Synthesis of potential peptide substrates.
The peptide substrates were generated using a standard solid phase peptide synthesis
protocol outlined previously (58). Briefly, an automatic Intavis AG peptide synthesizer was
used to synthesize free peptides using 9-fluorenylmethyl-oxycarbonyl (Fmoc) chemistry.
Rink amide resin (Rink-NH2, Product ID: S30132, RAPP POLYMERE, Tuebingen,
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Germany) was used to couple the first amino acid during the initial synthesis cycle. In each
synthesis cycle, the carboxyl group of an Fmoc-protected amino acid (FmocAA-COOH)
was linked to the amine group of the previous amino acid (or the Rink-NH2 amine in the
case of the initial synthesis cycle) through an amide bond. All unoccupied amine groups
were then blocked (acetylated) by acetic anhydride to prevent incorrect amide bond
formation in subsequent cycles. Next, the Fmoc group was removed by piperidine (deprotection) to release the free amine group for coupling to the carboxyl group of the next
amino acid residue.
On completion of synthesis, the free peptide-resin was incubated in a mixture
containing 95% Trifluoroacetic acid (TFA), 3% Triisopropyl silane (TIPS) and 2% H2O to
deprotect side chains and cleave the peptide from Rink-resin simultaneously. The cleavage
mixture containing the free peptide is then drained via vacuum from the tubes containing
the Rink-resin. The cleavage mixture containing the peptide products was then washed
(repeated three times) with 1 ml of pre-cooled ether followed by centrifugation at 3000 ×
g for 3 minutes and the supernatant was removed in order to precipitate and clean the free
peptide products. After allowing the peptides to dry overnight they were resuspended in
MilliQ water, aliquoted and stored at -20ºC. A list of the synthetic peptide sequences as
well as calculated and measured masses are in Table 1.1.

1.2.5 Mass spectrometry validation of peptides.
Matrix-assisted laser desorption/ionization with a time-of-flight analyzer (MALDI-TOF)
mass spectrometry was used to characterize the molecular weights of the synthesized
peptide substrates (1.2.4) to validate successful synthesis. Briefly, a MALDI matrix
consisting of alpha-cyano-4-hydroxycinnamic acid (CHCA) was prepared as 5 mg/ml in 6
mM ammonium phosphate monobasic, 50% acetonitrile, and 0.1% trifluoroacetic acid. An
aliquot of the matrix was then mixed with the synthesized peptide samples at 1:1 ratio (v/v).
MALDI-TOF mass spectrometric data were obtained using an AB Sciex 5800
TOF/TOF System, MALDI TOF (Framingham, MA, USA). Data acquisition and data
processing were respectively done using a TOF/TOF Series Explorer and Data Explorer
(AB Sciex). The instrument is equipped with a 349 nm Nd:YLF OptiBeam On-Axis laser.
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The laser pulse rate was 400 Hz. Reflectron positive mode was used. Reflectron mode was
externally calibrated at 50 ppm mass tolerance. Each mass spectrum was collected as a sum
of 1000 shots. A representative spectrum of a single synthesized peptide substrate is shown
in Figure 1.3 and a complete collection of the MALDI-TOF spectrum can be found in
Appendix 1, Figure S1.1.

1.2.6 Kinase activity assays.
The activity of each Akt1 phospho-form was characterized by performing a quantitative in
vitro kinase assays in the presence of 200 µM of a given potential substrate peptide (Table
1.1). Assays were performed in a reaction buffer consisting of 3-(N-morpholino)propanesulfonic acid (MOPS, 25 mM, pH 7.0), 12.5 mM β-glycerolphosphate, 25 mM
MgCl2, ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA, 5 mM,
pH 8.0), ethylenediaminetetraacetic acid (EDTA) (2 mM), ATP (0.02 mM), and 0.4 µCi
(0.033 µM) γ-[32P]-ATP.
Each reaction (30 µL reaction volume) was performed in triplicate, representing
three independent enzyme reactions. The reactions were initiated with addition of enzyme
and incubated at 37ºC. The t = 0 time point represents a control that lacks enzyme. Time
points were taken over a 5 min time course at t = 1 min, 2 min, 3 min and 5 min. As
previously (15,16), reactions were initiated by the addition of Akt1 (1.8 pmol of pAkt1S473,
0.36 pmol of pAkt1T308, or 0.09 pmol of ppAkt1T308,S473). Different concentrations of each
phosphor-form were used in the in vitro kinase assays to accommodate the varying levels
of activity of each of the phosphor-forms, as was done previously (15). The enzyme
concentration was adjusted to enable linear increase in reaction product during the reaction
time, which allows accurate measurement of the initial velocity. To normalize for the effect
of enzyme concentration, enzyme activities were later compared as apparent rates (kapp,
vo/[enzyme]).
Aliquots of each reaction were quenched at each time point by spotting 3 μl of each
reaction on P81 paper (59). Following spotting, the 3 μl spots were first allowed to dry,
then were washed with 1% phosphoric acid (3×10 min), then washed in 95% ethanol (1×5
min), and finally allowed to air-dry completely. Incorporation of γ-[32P] from the γ-[32P]-
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ATP into the potential substrate peptides was detected by exposing the P81 paper to a
phosphor-imaging screen. The γ-[32P]-peptide products were imaged and quantitated using
a Storm 860 Molecular Imager and ImageQuant TL software (GE Healthcare, Mississauga,
ON, Canada). The phosphor-images of each reaction are in Appendix 1 (Figures S1.2 and
S1.3).
Akt1 activity is reported as initial velocity (v0 fmol or pmol of phospho-peptide
produced per min) of the reaction. v0 is the slope of linear portion of the time course as
before (15,16). To compare Akt1 activity values between different Akt1 phosphorylated
variants, we determined apparent catalytic rate constants kapp (v0/pmol of Akt1). Negative
control assays were collected as a single time point (in triplicate) 10 minutes after the
initiation of the reaction. To derive a v0 from the negative control spots, the quantitated
level of transferred γ-[32P]-ATP was divided by the number of minutes that the reaction
had undergone (10 minutes) to result in a v0 that could be compared to the treatment groups
(Figure S1.4).

1.3 Results

1.3.1 Peptide synthesis and characterization.
In total, I synthesized 26 different peptides via solid phase peptide synthesis (Table 1.1).
The peptides corresponded to potential Akt1 substrate motifs. These motifs ranked highest
in database searches of the human phospho-proteome. The search relied on position
specific score matrices that were derived from oriented peptide arrays that we had assayed
previously with each Akt1 variant (14). The oriented peptide arrays reveal specific amino
acid preferences at each location in the Akt1 target consensus motif. By scoring the known
human proteome (44) with these matrices, both known and putative Akt1 substrates are
among the top scoring hits (14). Moreover, separate PSSM scoring systems were developed
for each of the different Akt1 phospho-forms, allowed us to identify potential Akt1
substrates that may display selectivity towards a specific Akt1 phospho-form.
Database searches using a separate PSSM developed for each Akt1 phospho-form
(pAkt1S473, pAkt1T308, ppAkt1S473,T308) were used rank and select 10 potential substrate
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peptides for each phospho-form (Table 1.1). Each phosphorylated peptide motif in the
database (44) was ranked based on three separate PSSM scoring systems, which predicted
the likelihood that a given phosphorylated motif the in database was a substrate of the
corresponding Akt1 phospho-form. We confined our peptides to those that have been
identified to be phosphorylated yet the upstream is not known or not known to include
Akt1.
The peptide substrates were synthesized using solid state peptide synthesis (see
Methods, Section 1.2.4). Quality of the synthetic peptides was determined using Matrixassisted laser desorption/ionization with a time-of-flight analyzer (MALDI-TOF) mass
spectrometry. A representative MALDI-TOF spectrum acquired from one of the peptide
substrates of is shown in Figure 1.3. The spectrum positively identified the presence of the
expected peptide sequence by the presence of a sole major peak at the expected molecular
weight of the peptide. For some peptides (E.g. the peptide derived from KCNH2
[QRKRKLSFRRRTD]), there was a discrepancy of 18 Da between the theoretical and
observed masses of the synthesized peptide due to mass-spec ionization induced thermal
decomposition (TD) (53). TD can cause peptide dehydration (mass – 18 Da) of peptide
molecules in cases where the peptide contains a C-terminal aspartic acid. The MALDITOF spectrum for the remaining synthetic peptides are provided in Appendix 1 (Figure
S1.1).

1.3.2 Quantifying the activity of Akt1 phospho-forms.
Each of the Akt1 phospho-forms were purified using affinity chromatography (Figure 1.4
and S1.5). Previous investigations from our lab have determined that the deletion of the PH
domain from Akt1 abolishes its auto-inhibitory activity and improves the purification of
Akt1 by increasing its solubility (15). Thus, the Akt1 phospho-forms used in this present
study (Akt1 residues 109-472) lacked a PH domain. We previously characterized each
Akt1 phospho-form biochemically and with mass spectrometry to confirm site-specific
phosphorylation for each Akt1 variant produced in this manner (15,16)In order to verify
the activity of the purified Akt1 phospho-forms produced in this study, in vitro kinase
assays were conducted using the known Akt1 substrate GSK-3β (Figure S1.2 and S1.3).
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Based on these data, apparent rate constants were determined for independent Akt1
preparations (Figure 1.5).
Activity levels for all three Akt1 phospho-forms prepared in this study were
consistent with previously prepared Akt1 phospho-forms (15,16) (Figure 1.5). To confirm
consistent activity between the Akt1 preparations, activity values from previously purified
and experimentally validated (15,16) Akt1 phospho-forms were compared to the new
preparation used here (Figure 1.5). These data demonstrate the consistency of the enzyme
activity that is achievable using this method and supports the identity and functionality of
the Akt1 preparations used below. Both sets of activity data (Figure 1.5) were obtained
using the same in vitro kinase assay protocol (see Methods, Section 1.2.6).
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Figure 1.3. Representative MALDI-TOF spectrum of a synthesized peptide substrate.
MALDI-TOF mass spectrometric data were obtained using an AB Sciex 5800 TOF/TOF
System, MALDI TOF (Framingham, MA, USA). Data acquisition and data processing
were respectively done using a TOF/TOF Series Explorer and Data Explorer (both from
AB Sciex). The x-axis position of the blue peaks is measured in mass/charge number of
ions (m/z). Here, the charge number of ions (z) is equal to 1 and so the (m/z) value is a
measure of molecule size (m, in Daltons) which corresponds to the molecular weights of
the analyzed molecules. The large peak (A) corresponding to the molecular weight of
1731.03 Da confirms the identity of the peptide substrate as well as the integrity of the
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solid phase peptide synthesis protocol used to synthesize the peptides. The peptide
sequence and theoretical molecular weight of the peptide is indicated.
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Figure 1.4. Purification of phosphorylated Akt1 (pAkt1T308). (A) Coomassie stained
SDS-PAGE and (B) Western blot of the flow through (FT), washes, elutions, and final
pooled product (P1) of the affinity chromatography used to purify pAkt1 T308 from
recombinant production in E. coli. The concentration of final protein product was 7.2 μM
with a total yield of 32 µg/l of E. coli culture. ΔPH-Akt1 has an expected molecular weight
of 45 kDa.
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Figure 1.5. Batch to batch consistency in Akt1 phospho-form activity across different
preparations. The apparent catalytic activity (kapp, fmolsubstrare/min/pmolenzyme) of the three
active Akt1 phospho-forms: pAkt1S473 (left panel), pAkt1T308, and ppAkt1T308,S473 (right
panel) is shown here. All activity assays were conducted following the kinase assay
protocol (see Methods) using 200 μM of the GSK-3β peptide (SGRPRTTSFAESCKP) as
the substrate target for Akt1. The enzymes (Preparation 1) represented by the blue-striped
bars were the ones purified, classified and utilized in this study (Figures 1.4, S1.5) while
activity represented by the white bars (Preparation 2) were used in our previous work
(15,16). Error bars represent 2 standard deviations about mean value for 3 independent
enzyme reactions (n=3).

1.3.3 Activity of predicted Akt1 substrate peptides.
The 26 predicted Akt1 peptide substrates were then subjected to kinase assays. The activity
data are based on a reaction time course during which the transfer of radiolabeled phosphate
to the substrate peptide is quantitated (Figure S1.2-S1.4). The initial velocities of the
enzymatic reaction (v0) were determined by linear regression of the time courses. The initial
velocity data (Figure S1.6) were used to compare Akt1 activity over different peptide
substrates including a known Akt1 substrate GSK-3β positive control. Negative control
values were derived following the same in vitro kinase assay protocol outlined above using
a variant of the GSK-Sβ peptide that lacks the phosphorylatable Ser residue at the S9
position: GSK-3β(S9A) variant (Figure S1.4).
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Figure 1.6. Apparent catalytic rate (kapp) of the phosphorylation reaction catalyzed
by each of the indicated Akt1 phospho-forms. (A) pAkt1S473, (B) pAkt1T308, and (C)
ppAkt1T308,S473. Each bar represents the average kapp value of 3 replicates and the value of
each replicate is indicated by a closed circle. All three Akt1 phospho-forms were tested
using the known Akt1 substrate GSK-3β (SGRPRTTSFAESCKP, red bars) as a standard
to assess the activity of the Akt1 preparations, as well as a negative control variant of GSK3β: GSK-3β (S9A) (SGRPRTTAFAESCKP, left) to obtain minimal activity values for
each phospho-form. GSK-3β (S9A) contains an un-phosphorylatable alanine residue in
place of the serine residue that is normally phosphorylated by Akt1. Error bars represent 2
standard deviations about mean value for 3 independent reactions (n=3).
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The predicted peptide substrates were assayed using the same Akt1 phospho-form
that was used to develop the PSSM scoring system that predicted the given peptide (Table
1.1). From these preliminary assays, the 3 highest and 3 lowest scoring peptides for each
variant were selected for additional kinase assays conducted with the remaining two Akt1
phospho-forms. For example, from the initial assays of the 10 peptides predicted to be
substrates of pAkt1S473 (Table 1.1) the peptides with the 3 highest (CMTM4, LPHN3 and
PITPNM2) and 3 lowest (KIAA1109, HRH1 and ZNF256) activity values were
subsequently assayed with the remaining two Akt1 phospho-forms: pAkt1T308 and
pAkt1T308,S473. In total, 16 of the 26 total peptides were assayed using all three Akt1
phospho-forms and the corresponding activity data (v0) is outlined in Figure S1.6.
Different concentrations of each Akt1 phospho-form were used in the kinase assays
(see Section 1.2.6) to permit accurate calculation of v0 from the linear portion of the
phosphorylation reaction time course (Figure S1.6). To account for these differences in
protein concentration when comparing activity levels across the Akt1 phospho-forms, v0
values were divided by the Akt1 enzyme concentration used in the given assay to arrive at
the apparent catalytic rate (kapp) of each reaction (Figure 1.6).
The kapp values obtained here agree with the previously observed trend in Akt1
activity (15,16), in which the pAkt1S473 enzyme shows significant activity above the
negative control, across all substrates tested (p < 0.0255 for all substrates), that is far below
the activity level for the pAkt1T308 and ppAkt1T308,S473 enzymes. We also observed that
ppAkt1T308,S473 is more active than pAkt1T308 on the GSK-3β peptide, as we noted before
(14-16) (Figure 1.5). With respect to kapp values, ppAkt1T308,S473 was significantly more
active (p = 0.0053) with the peptide derived from RAB11FIP2 than with the known Akt1
substrate GSK-3β. Pairwise comparisons of kapp values for each peptide tested between
pAkt1T308 and ppAkt1T308,S473 revealed that ppAkt1T308,S473 was at least as active as
pAkt1T308 with 6 (33%) of the 18 peptides tested. Peptides representing ZNF256, CMTM4,
FMO2, TRAPPC1, BTBD11 and KIAA1109 showed no significant difference in kapp for
ppAkt1 compared to pAkt1T308. The doubly phosphorylated enzyme was more active (p <
0.009) with 12 (66%) of the peptides. Notably, the 6 peptides that had similar kapp values
for both pAkt1T308 and ppAkt1T308,S473 were also the 6 least active peptides for both
phospho-forms.
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Figure 1.7. Normalized apparent catalytic rate (kapp) of the phosphorylation reaction
catalyzed by different Akt1 phospho-forms on predicted Akt1 substrate peptides. The
kapp values of each phospho-form (pAkt1S473 (blue, open bars), pAkt1T308 (orange, solid),
and ppAkt1T308,S473 (orange, checkered) have been normalized using each phospho-form’s
kapp values for the known Akt1 substrate standard GSK-3β. Each of the peptides shown
here were individually subjected to in vitro kinase assays (triplicate) with each of the three
Akt1 phospho-forms. Error bars represent 2 standard deviations about mean for 3
independent reactions (n=3).
In order to estimate the relative preference or selectivity of each Akt1 phosphoform for the series of peptides, normalized kapp values for each of the peptides tested were
plotted (Figure 1.7). Normalization was based on setting the kapp for each Akt1 variant for
the positive control GSK-3β peptide to 1.0. The peptides displayed in Figure 1.7 are
ordered bases on ascending kapp values for on activity with ppAkt1T308,S473. Figure 1.7 also
contains the kapp values of the positive control GSK-3β as well as the negative control GSK3β (S9A) across all three Akt1 phospho-forms. Normalization of the kapp values revealed
trends in the substrate selectivity of pAkt1S473 compared to the pAkt1T308 and
ppAkt1T308,S473.
From the normalized kapp values, I derived phospho-form selectivity values by
dividing one Akt1 phospho-form’s kapp value for a given peptide by the average of the
remaining two phospho-form’s kapp values for the same peptide. For example, to arrive at
a selectivity value for pAkt1S473 with ZNF256, I divided pAkt1S473 normalized kapp value
for ZNF256 (0.43) by the average of pAkt1T308 and pAkt1T308,S473’s normalized kapp values
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for ZNF256 (0.06) to get pAkt1S473’s selectivity value for ZNF256 (6.7 fold). A selectivity
value of 1 indicates that the phospho-form is roughly as active on the given peptide as the
other two phospho-forms, where as a selectivity value above or below 1 indicates that the
given phospho-form is more or less active on the given peptide than the other two phosphoforms, respectively. The selectivity values are presented in Table 1.2. From these values,
it is apparent that the pAkt1S473 phospho-form has a strong selectivity (> 2-fold) towards
the peptide substrates derived from ZNF256, KIAA1109, CMTM4, FMO2, TRAPPC1 and
BTBD11. Moreover, the ppAkt1T308,S473 phospho-form appears to have a strong selectivity
(> 2-fold) towards a distinct set of peptide substrates derived from GRAMD1C, SRRM4,
CYSLTR1, and RAB11FIP2. Taken together these results support the idea that Akt1
phosphorylation status plays an important role on determining kinase-substrate specificity.

Table 1.2. Akt1 phospho-form selectivity values
Phospho-form
Relative selectivity value
(x-fold)
gene

protein name

peptide sequence

pI
pAkt1

ZNF256
KIAA1109
CMTM4
FMO2
TRAPPC1
BTBD11
HRH1
SCN2A
LPHN3
CDCA7L
PITPNM2
KCNH2
GRAMD1C
SRRM4
CYSLTR1
RAB11FIP2

zinc finger protein 256
uncharacterized protein
MARVEL transmembrane 4
dimethylaniline monooxygenase
trafficking protein particle complex 1
ankyrin repeat and BTB/POZ
histamine H1 receptor
sodium channel protein type 2 alpha
adhesion G protein-coupled receptor L3
cell division cycle-associated 7-like
phosphatidylinositol transfer protein 2
potassium channel H2
GRAM domain containing 1C
serine/arginine repetitive matrix protein 4
cysteinyl leukotriene receptor 1
Rab11 family-interacting protein 2

THQRVHTGTRPYM
TSKRALSTWGPVP
EIQRLDTFSYSTN
FHTRFRSMLRNVL
FRSRLDSYVRSLP
MHSRHNSFDTVNT
TWKRLRSHSRQYV
RKRRSSSYHVSMD
YSKRTMTGYWSTQ
RRHRISSFRPVED
PRKRSDSSTYELD
QRKRKLSFRRRTD
LRRRRRTFNRTAE
KRRRSSSYSPSPV
FRKRLSTFRKHSL
PHRRTLSFDTSKM

10.83
11
4.37
12.3
10.74
6.69
11.72
10.9
9.7
11.52
6.54
12.18
12.3
11.72
12.31
10.84

pAkt1 ppAkt1

S473

T308

T308,S473

6.7
2.9
8.3
4.4
3.6
2.5
1.0
2.1
1.4
1.7
0.8
1.1
0.8
0.8
0.5
0.6

0.3
0.5
0.2
0.2
0.3
0.4
0.6
0.3
0.6
0.4
0.8
0.4
0.4
0.5
0.7
0.7

0.3
0.6
0.2
0.5
0.6
0.8
1.5
1.0
1.0
1.3
1.5
2.0
2.4
2.1
2.3
2.3

Selectivity values of each Akt1 phospho-form are presented for each of the peptides listed.
Selectivity values were derived from the normalized kapp values of each Akt1 phosphoform for each of the peptides listed.
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1.4 Discussion

1.4.1 The clinical relevance of phosphorylation status-dependant substrate specificity.
Effective therapeutic targeting of Akt1 remains to be a challenge. Small molecule inhibitorbased strategies are often plagued with unwanted off target effects that lead to dose-limiting
toxicities (35,60). These unwanted side effects can be attributed, at least in part, to the
structural and functional similarities that are shared between Akt1 and a wide range of
protein kinases in the AGC kinase family (1,2). Further complicating this issue are the Akt
isozymes, Akt2 and Akt3 which likewise share exceptional similarity with Akt1. All three
kinases share ~80% sequence identity in the kinase domain, 60% in the PH domain and
26% in the hinge domain that connects the kinase and PH domains across

all

three

isozymes. Unwanted inhibition of related kinases and alternative Akt isozymes can disrupt
or reverse the intended therapeutic benefits associated with targeting Akt1.
For instance, independent studies of breast cancer in transgenic mouse models have
shown that in certain cellular contexts, Akt1 and Akt2 have distinct and opposing effects
on tumour migration and metastatic dissemination (61,62). The suppression or deletion of
Akt2 interferes with glucose homeostasis (35,60) particularly in adipose tissue (63) and
can ultimately result in diabetes mellitus-like syndromes (64). Thus, small molecule
inhibition of Akt1 would be ineffective in these cases, unless the inhibitor were able to
selectively target Akt1. This example outlines the importance of being able to target a
specific subset of Akt enzymes in order to achieve the desired therapeutic effect.
Accordingly, the focus of much research has centered around the design of Akt1-isozyme
specific inhibitors (65).
Yet, selectivity beyond individual Akt isozymes may prove to be necessary for
future therapeutics that aim to further minimize unwanted side effects. Phosphorylation of
Akt1 at position S473 has been shown previously to alter the substrate specificity of Akt1
to include members of the FOXO transcription factor family and the proline rich Akt1
substrate (PRAS40) (66). Along with the work presented here, we have elsewhere
established that each differentially phosphorylated form of Akt1 (pAkt1S473, pAkt1T308,
pAkt1T308,S473) selectively phosphorylates different subsets of known substrates (14),
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Further, our work investigating differentially phosphorylated forms of Akt1 has revealed
that selective inhibition of individual Akt1 phospho-forms is possible (16).
Taken together, the results of our previous investigations into the phosphorylationdependant activity(15), inhibitability(16) and substrate specificity(14) of Akt1 suggest that
phosphorylation status constitutes a novel targetable Akt1 property that should be
considered during the future development of Akt1-specific inhibitors in order to further
minimize potential off-target effects. However, in order to determine which Akt1 phosphoform would be most therapeutically beneficial to target, we must first better characterize
which subsets of substrates are acted on by each Akt1 phospho-form.

1.4.2 Comparing the genetic code expansion system to alternative methods of
producing activate Akt1
In this report I utilized genetic code expansion within an E. coli system to
incorporate the unnatural amino acid phosphoserine into Akt1 at position 473. When used
in combination with co-expression of Akt1’s upstream kinase PDK1, the genetic code
expansion methodologies employed here allow us to produce site specifically
phosphorylated variants of Akt1 that are otherwise difficult to isolate. Prior to the
development of the genetic code expansion system used here, initial attempts at producing
recombinant active Akt1 employed the use of phospho-mimetic mutations (67). In the case
of recombinant Akt1, phospho-mimetic mutations involve replacing the serine at position
473 with glutamate as its side chain was proposed to mimic the structure and function of a
phosphorylated serine residue. However, during the development of the phosphor-mimetic
approach to active Akt1 production, the authors were unable to compare the activity of
their phospho-mimetic S473E Akt1 construct to Akt1 that contained pSer at position 473
(67). Using the genetic code expansion system described here, our lab produced
recombinant Akt1 with pSer at position 473 and was able to demonstrated that phosphomimetic substitutions do not accurately mimic the functional role of Akt1 activation that is
achieved by the phosphorylation of S473 (15). These findings call into question the validity
of phospho-mimetics as a replacement for phosphorylation and also demonstrate the
applicability of the Akt1 constructs produced by the genetic code expansion system
described here.
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1.4.3 Validating predicted Akt1 substrates.
Using our established method (15,16) to produce site-specifically phosphorylated variants
of Akt1, we recently conducted in vitro kinase assays of OPALs that contained degenerate
peptides representative many putative Akt1 substrates (14). By testing each separate Akt1
phospho-form (pAkt1S473, pAkt1T308, ppAkt1T308,S473) using the OPAL, we were able to
detect differences in substrate specificities for each of the Akt1 phospho-forms. Further,
using a method derived from Scansite (68), we were able to develop a PSSM scoring
system that evaluated and predicted potential substrates for each of the Akt1 phosphoforms based on the activity data generated from the in vitro kinase assays conducted on the
OPALs. Previously, the inability to produce Akt1 in site-specifically phosphorylated forms
had precluded the study of the effects of individual phosphorylation events on substrate
specificity. Now, we have developed a scoring system that enables us to predict novel Akt1
substrates for the purpose of better characterizing the scope of substrates that are targeted
by each Akt1 phospho-form.
Here, I synthesized and validated several potential Akt1 substrates, and some
showed specificity toward individual Akt1 phospho-forms. To accomplish this, I
synthesized potential peptide substrates based on the predictions derived from the peptide
arrays (14). The results presented here are congruent with the findings of our initial
investigations into phosphorylation-status dependent Akt1 activity (15,16) and substrate
specificity (14). In particular, the general trend of Akt1 activity observed here: pAkt S473 <
pAkt1T308 < ppAkt1T308,S473, mirrors the trend observed across three previous studies using
our methods of producing phosphorylated Akt1 variants (14-16).
Finally, Akt1 was shown to phosphorylate peptides derived from previously
uncharacterized substrates in vitro and many of the novel peptide substrates were
phosphorylated to a degree comparable to the well-established Akt1 substrate GSK-3β.
The use of peptides derived from potential substrates represents only the first step towards
the validation of previously uncharacterized Akt1-substrate interactions. Indeed, the results
presented here validate the peptide array approach in predicting novel Akt1 substrates.
However, the use of peptide substrates alone can not validate a true interaction between
Akt1 and the protein from which the peptide is derived. For example, conformational
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limitations may exist within the fully intact protein that preclude Akt1 phosphorylation of
the peptide region that is represented by the experiments presented here. Full validation of
the Akt1-substrate interaction will therefore require further testing cellular and in vivo
model systems using fully intact substrate proteins.
1.4.4 Discovering novel Akt1 phospho-form-specific substrates.
The selectivity values presented in Table 1.2 showcase novel Akt1 phospho-form-specific
substrates that were validated in this present study. Interestingly, none of substrates
validated here were selective for the pAkt1T308 enzyme. The lack of difference in substrate
selectivity between pAkt1T308 and ppAkt1T308,S473 mirrors the results of our initial
investigation into phosphorylation-dependant substrate specificity of Akt1 (14).
In this present study, I was able to identify a total of 11 previously unidentified
Akt1 substrates that showed significant levels of phosphorylation in kinase assays with
their respective Akt1 phospho-forms. In each case, significant activity was detected, i.e.,
kapp substrate > kapp negative control GSK-3β(S9A) (p < 0.0001 in all cases). Of these 11
novel substrates, 7 were relatively selective (Table 1.2 selectivity values > 2) for pAkt1S473
(ZNF256, KIAA1109, CMTM4, FMO2, TRAPPC1, BTBD11, SCN2A) and 4 were
relatively selective for ppAkt1T308,S473 (GRAMD1C, SRRM4, CYSLTR1, RAB11FIP2)
(Sequences available in Table 1.1). Relative selectivity indicates that the given substrate
was highly active for the indicated Akt1 phospho-form and lowly active for the remaining
two phospho-forms.
The preferred substrate consensus motif of the 11 novel Akt1 substrates observed
here concur with the established consensus motif R-5X-4R-3X-2X-1S/T0ϕ1 and also align with
the patterns that were observed previously . The substrates that lacked an Arg residue at
the -5 position were disfavoured by both pAkt1T308 and pAkt1T308,S473 (selectivity values <
1, Table 1.2) but were favoured by pAkt1S473 (selectivity values > 1, Table 1.2). The same
pattern was observed in all 7 of the novel peptides that were validated as pAkt1S473selective substrates (Tables 1.1, 1.2). Accordingly, the 4 novel peptides that were validated
as being ppAkt1T308,473-selective substrates all contained an Arg residue at the -5 position,
which is likewise in agreement with our findings on the effect of phosphorylation on Akt1
substrate selectivity (14).
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1.4.5 Novel pAkt1S473-selective substrates.
Of the 7 novel peptides validated in this study, the peptide derived from the MARVEL
transmembrane 4 (CMTM4) protein had the highest selectivity value for pAkt1S473.
Accordingly, the CMTM4 peptide also exhibited the highest kapp of all the peptides tested
with pAkt1S473, similar to the kapp for GSK-3β. Interestingly, the peptide derived from
CMTM4 had the lowest isoelectric point of all the peptides tested, perhaps indicating the
preference or higher tolerance for negatively charged substrates in pAkt1 S473. CMTM4 is
a ubiquitously expressed transmembrane protein that has recently gained attention as a
potential phenotypic contributor in various cancers (69-73). However, as of yet, there is
minimal information on the relationship between Akt1 and CMTM4 activity, and none on
the role of phosphorylation at the CMTM4 T208 site that was the source of the peptide
used in this study. Topology predictions using the transmembrane topology prediction
software Phobius (74) suggest that the T208 site is located within the cell cytosol and is
thus would be accessible for phosphorylation by Akt1.
The function of CMTM4 with respect to its role in oncogenic phenotypes appears
to be highly context dependant. In clear cell renal cell carcinomas, restoration of CMTM4
expression induces G2/M cell cycle arrest (70). In patients with hepatocellular carcinomas,
the expression of CMTM4 was reduced compared to matched adjacent non-tumor tissues,
and this reduced expression was associated with decreased overall survival rates (73). In
colorectal adenocarcinomas cell lines, over-expression of CMTM4 (in the CMTM4SW480 cell line) was associated with impeded cell proliferation, reduced migration and
reduced levels of Akt phosphorylation. (72). In SW480 cells, CMTM4 expression was
found to be inversely related to the phosphorylation of Akt1, and the tumour-suppressive
functionalities observed with CMTM4 overexpression could be mimicked in the CMTM4SW480 cell line by direct chemical inhibition of Akt using LY294002 (72). Unfortunately,
due to the use of pan-Akt antibodies to detect the changes in Akt-phosphorylation, it is
unclear which specific Akt1 phospho-form (or combination of phospho-form s) was
affected by CMTM4 over expression.
Conversely, in some cellular contexts CMTM4 appears to promote rather than
prevent oncogenic phenotypes. Along with its homolog CMTM6, CMTM4 expression has
been linked to the stabilization and longevity at the cell surface of the programed death
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ligand-1 (PD-L1) causing PD-L1-mediated T-cell suppression and subsequent tumor
survival in multiple cell lines and primary human dendritic cells (69,75). The fact that
CMTM4 has separate, seemingly divergent roles in cancer phenotypes may present similar
problems with respect to the development of traditional small-molecule-based inhibitors.
Just as global Akt inhibition can dys-regulated metabolic pathways (64), it may be the case
that initial attempts at CMTM4-inhibition may result in unwanted side-effects stemming
from the reduction of the tumour suppressor activities. Instead, approaches aimed at
therapeutic modulation of CMTM4 activity should begin with an investigation into the
mechanisms responsible for the CMTM4 over/under expression that has been observed in
the examples of cancer. An investigation into the potential functional role of CMTM4 T208
phosphorylation is warranted and would further validation in cells and ultimately animal
models, to demonstrate CMTM4 as a bona fide Akt1 target.
1.4.6 Novel ppAkt1T308,S473-selective substrates.
Of all the peptides tested with ppAkt1T308,S473, the peptide derived from RAB11FIP2 had
the second highest kapp value and was the only peptide to achieve a kapp value that was
significantly higher than the known Akt1 substrate GSK-3β (p = 0.0053). RAB11FIP2
function involves the regulation of endosomal vesicle recycling between the endosomal
recycling compartment and the plasma membrane (76). RAB11FIP2 is not known to be a
direct target of Akt1, though independent studies have posited functional(77) as well as
spaciotemporal(76) links between the two proteins. A recent study investigating the
relationship between RAB11FIP2 expression and colorectal cancer progression
demonstrated that the Akt1/PI3K pathway was involved in the RAB11FIP2-mediated
expression of the oncogenic Matrix metalloproteinase 7 (MMP7) (77). However, a recent
investigation into subcellular localization has demonstrated that RAB11FIP2 colocalizes
and indeed interacts with phosphatidylinositol-(3,4,5)-trisphosphate (PIP3) in a manner
similar to Akt1 (76). Like the Akt1 PH domain, RAB11FIP2 contains a domain which
promotes association with PIP3 at the cellular membrane called the C2 domain membrane.
Thus, Akt1 and RAB11FIP2 may co-localize in response to the same cellular stimuli that
converts PIP2 to PIP3.
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The peptide derived from CysLTR1 had the highest kapp of all the peptides tested
with ppAkt1T308,S473, on par with the kapp value of the known ppAkt1T308,S473 substrate:
GSK-3β (p = 0.0723). CysLTR1 are cell surface receptors of the G-protein coupled
receptor family that recognize a family of inflammatory lipid mediators called cysteinyl
leukotrienes (78). CysLTR1 is a multifunctional mediator of allergic rhinitis, both as a
mediator of bronchoconstriction and as an initiator of secondary messenger systems
involved in immune cell development and immune cell response (78,79). CysLTR1
immunomodulation in allergic rhinitis was determined to involve a concurrent increase in
the level of active, phosphorylated ERK1/2. Phosphorylated ERK1/2 is involved in cell
adhesion, proliferation, differentiation, and cell cycle progression (80) and the inhibition
of ERK1/2 has been shown to reduce allergic inflammation (81). CysLTR1 is not known
to be an Akt1 target, nor have any direct interactions between CysLTR1 and Akt1 been
noted in the literature. However, cross-talk between the Akt1/PI3K and ERK1/2 signalling
pathways has been previously implicated to be involved in both arteriogenisis (82), as well
as cell motility and invasion (83). Thus, the link between Akt1 and CysLTR1 may be direct
via Akt1-mediated phosphorylation of CysLTR1’s T308 residue (the motif represented
here) or indirectly through the CysLTR1-ERK1/2-Akt1 axis.
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Figure S1.1. MALDI-TOF spectrum of a synthesized peptide substrate. MALDI-TOF
mass spectrometric data were obtained using an AB Sciex 5800 TOF/TOF System, MALDI
TOF (Framingham, MA, USA). Data acquisition and data processing were respectively
done using a TOF/TOF Series Explorer and Data Explorer (both from AB Sciex). The xaxis scale is equivalent to mass in Daltons (Da) as the charge number of ions (z) is equal
to 1. The large peak (A) corresponding to the molecular weight of 1731.03 Da confirms
the identity of the peptide substrate as well as the integrity of the solid phase peptide
synthesis protocol used to synthesize the peptides.
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50

Figure S1.2. Radiograph detecting the presence of γ-[32P]-ATP in peptides
phosphorylated by pAkt1S473 and pAkt1T308. Time courses (minutes) of the in vitro
kinase assay catalyzed by the indicated phospho-form of Akt1 on the indicated peptide
substrate. Each spot was generated by dispensing 3 μl of kinase assay reaction mixture onto
P81 paper at the indicated time point after the initiation of the reaction. Assays were
performed in triplicate (R1-R3). Three spots (Standard) correspond to the γ-[32P]-ATP
standards which were used to calculate the relationship between spot intensity and [γ-[32P]ATP].
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Figure S1.3. Radiograph detecting the presence of γ-[32P]-ATP in peptides
phosphorylated by ppAkt1S473,T308. Time courses (minutes) of the in vitro kinase assay
catalyzed by the indicated phospho-form of Akt1 on the indicated peptide substrate. Each
spot was generated by dispensing 3 μl of kinase assay reaction mixture onto P81 paper at
the indicated time point after the initiation of the reaction. Assays were performed in
triplicate (R1-R3). Three spots (Standard) correspond to the γ-[32P]-ATP standards which
were used to calculate the relationship between spot intensity and [γ-[32P]-ATP].
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Figure S1.4. Radiographs created by Nileeka Balasuriya that detect the presence of
γ-[32P]-ATP in control peptides phosphorylated by pAkt1S473, pAkt1T308, and
ppAkt1S473,T308. Spots of the in vitro kinase assay catalyzed by the indicated phosphoform of Akt1 on the indicated control peptide substrates. Assays were performed by
Nileeka Balasuryia in triplicate (R1-R3). Each spot was generated by dispensing 3 μl of
kinase assay reaction mixture onto P81 paper 10 minutes after the initiation of the reaction.
Three spots (Standard) correspond to the γ-[32P]-ATP standards which were used to
calculate the relationship between spot intensity and [γ-[32P]-ATP].
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Figure S1.5. Purification of phosphorylated Akt1 (pAkt1S473 and ppAkt1T308,S473).
Coomassie stained SDS-PAGE (A) and α-His immunoblot (B) of the intermediate and final
purification products of the affinity chromatography used to purify phosphorylated Akt1
variants from recombinant production in E. coli. P denotes the final purified and
concentrated Akt1 product, Pel/Sn denote samples of the ultracentrifuge pellet/supernatant
respectively, FT denotes the initial flow-through of the purification prior to the addition of
imidazole and W1, E1 and E2 denote the washes and elution treatments used to elute Akt1
(outlined in 1.2.3). The proteins presented here were used in the in vitro kinase assays in
this study (Figure S1.2 and S1.3) and are denoted as “preparation 1” in Figure 1.5.
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Figure S1.6. Initial velocities of the phosphorylation reaction catalyzed by each of the
indicated Akt1 phospho-forms. pAkt1S473 (A), pAkt1T308 (B), ppAkt1T308,S473 (C). Each
bar represents a separate reaction containing a different peptide substrate. All three Akt1
phospho-forms were tested using the known Akt1 substrate GSK-3β
(SGRPRTTSFAESCKP, red bold) as a standard to assess the activity of the Akt1
preparations, as well as a negative control variant of GSK-3β: GSK-3β (S9A)
(SGRPRTTAFAESCKP, gray bold) to obtain minimal activity values for each phosphoform. GSK-3β (S9A) contains an un-phosphorylatable alanine residue in place of the serine
residue that is normally phosphorylated by Akt1. Error bars represent 2 standard deviations
about mean value for 3 independent reactions (n=3).
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CHAPTER 2 – Expanding the Genetic Code of Bacillus subtilis
2.0 Abstract
Genetic code expansion enables organisms to incorporate unnatural amino acids into
proteins in response to a re-assigned codon. Commonly, the infrequently used UAG
(amber) codon in Escherichia coli is chosen to encode unnatural or non-canonical amino
acids. The co-translational incorporation of unnatural amino acids into proteins requires an
orthogonal translation system consisting of an engineered tRNA that can decode the reassigned codon, an aminoacyl synthetases to ligate the unnatural amino acids to the tRNA,
and an unnatural amino acid that is not toxic and cell permeable. By inserting the recoded
amber codon into the coding region of growth-essential genes, cell growth and survival
becomes dependant on both the functionality of the orthogonal translation system and the
provision of the otherwise unavailable unnatural amino acid. Previously, this system has
been implemented as a successful means of biocontainment in Escherichia coli. There is
yet, no such orthogonal translation system that functions in the gram-positive bacteria
Bacillus subtilis. The work presented here represents the pioneering effort towards the
development of an orthogonal translation system that functions to expand the genetic code
of B. subtilis to include Nε-acetyl-L-lysine. I designed, built, and performed initial tests on
an all-in-one plasmid that contains all the requisite genetic components of an orthogonal
translation system along with a built-in fluorescent GFP reporter to assay UAG readthrough. Stable integration of the entire orthogonal translation system in the B. subtilis
genome was achieved.

2.1 Introduction
2.1.1 Biotechnological applications of B. subtilis.
B. subtilis is an exceptionally well-characterized gram (+) bacteria with numerous
applications in both academic research and industry. B. subtilis has received the FDA
designation of Generally Recognised As Safe (GRAS), which means that products
biosynthesized by the organism are considered safe for contact and consumption by
humans (1). This designation, coupled with the organism’s innate ability to endure
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manufacturing and storage conditions, including oxygen-rich environments, osmotic stress
and heat (2,3), as well as proficiency at producing and excreting proteins and biomolecules
into its environment (4), has made B. subtilis an important organism across a broad range
of biotechnological applications.
In medicine, B. subtilis has garnered widespread interest as both an important
probiotic (5) and as a promising bacterial vaccine candidate (6,7). Moreover, the probiotic
effects of B. subtilis are relevant in the field of agriculture as recent studies on Broiler
chickens and white shrimp have demonstrated B. subtilis’ ability to ameliorate intestinal
bacterial imbalance which promotes growth and increases the yield of harvests (8,9).
From a financial perspective, however, B. subtilis has an outsized role in the field
of chemical and protein biomanufacturing. Nearly 900 tonnes of proteases, lipases, and
amylases (active ingredients in laundry detergents) are produced annually using B. subtilis
bio-reactors representing a yearly turnover of nearly 3 billion CAD (4). Although we are
still at the advent of bacteria-based biomanufacturing, as synthetic biology applications for
B. subtilis continue to grow, there will be increasing demands on researchers to improve
the underlying technologies that allow us to use these organisms to their full potential.

2.1.2 Orthogonal translation systems.
The demand for bacteria with new and improved capabilities for practical industrial
applications has been one of the major driving forces behind the emergence of the field of
synthetic biology. In recent years, synthetic biology has grown greatly due to the invention
of recombinant DNA technologies in E. coli (10). One such technology is the orthogonal
translation system (OTS), which enables expansion of the genetic code to produce proteins
with unnatural (uAA) or non-canonical amino acids (ncAA) beyond the standard 20
proteinogenic amino acids (11) (Figure 1.1).
To expand the natural translation system, it is important that the engineered
system does not interfere with or compromise the integrity of the natural components. The
orthogonal aaRS must only recognize and aminoacylate its cognate orthogonal tRNA with
a specific or desired unnatural amino acid. Orthogonality ensures that the engineered aaRS
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does not charge any of the 33 endogenous E. coli tRNAs with the uAA so that the uAA is
not incorporated randomly throughout the proteome. Likewise, the orthogonal tRNA must
not be charged with naturally occurring amino acids by any of the endogenous aaRSs
present in E. coli so that the OTS does not needlessly incorporate one of the naturally
occurring amino acids in place of an uAA at the UAG codon.
The OTS used here is composed of tRNAPyl-opt (12) and an optimized version of
the Nε-acetyl-L-lysyl-tRNA synthetase (AcKRS) (13) (Figure 2.2). AcKRS and tRNAPylopt

originate from the pyrrolysyl-tRNA synthetase (PylRS) and tRNAPylCUA pair derived

from Methanosarcina species (14,15). The PylRS system was first used to expand the
genetic code of E. coli in 2004 (15). To generate AcKRS, a crystal structure of PylRS in
complex with pyrrolysine (PDB accession code: 2Q7H, (16)) was used to determine key
PylRS residues that were within 6Å of pyrolysine’s pyrroline ring. Through mutation of
these residues, a variant (AcKRS) of PylRS was generated (13) that preferentially bound,
and charged tRNACUA with, Nε-acetyl-L-lysine (AcK) and to a lesser degree other similar
uAAs, including Nε-Boc-L-lysine (BocLys).
The variant of AckRS used here, contains a further 4 mutations (V31I, T56P,
H62Y, and A100E) which were derived by phage assisted continuous evolution experiment
that improved the yield of proteins containing unnatural amino acids by ~10-fold (17).
AcKRS in the experiments presented here refers to the use of this optimized version of
AcKRS. tRNAPyl-opt is a rationally evolved variant of tRNAPylCUA that has a 5-fold increased
capacity for AcK incorporation compared to the wild type tRNA Pyl (12). tRNAPyl-opt
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includes mutations in the acceptor and T stems of the tRNA that improved binding to E.
coli elongation factor-Tu (12).

Figure 2.1. Schematic representation of AcKRS and tRNAPyl-opt mediated decoding
of UAG codons in GFP mRNA. A) The components of the AcKRS/tRNAPyl-opt OTS
within the pDR111_AcKRS_GFP plasmid are presented. Three key genetic components;
the aminoacyl- tRNA Synthetase: AcKRS (flanked by sarA promoter and terminator,
blue), its orthogonal cognate tRNA: tRNAPyl-opt (flanked by SerT promoter and
terminator, orange), and the GFP reporter system (shown in C). The unnatural amino acid
Nε-acetyl-L-lysine (AcK) is not produced endogenously by B. subtilis nor are the genetic
components required to synthesize de novo AcK present in pDR111_AcKRS_GFP.
Instead, AcK must be directly supplemented (10 mM) into the growth media. B) The role
of each OTS component are outlined: AcKRS charges tRNAPyl-opt with AcK. C) The OTS
functions to decode nonsense UAG codons. When the ribosome is presented with a
premature UAG codon that would normally signal the end translation, it is instead
supplied with AcK-tRNAPyl-opt, which is incorporated into the growing peptide chain
allowing translation elongation to continue. In the system employed here, expression of
the full-length GFP protein requires a functioning OTS to decode an in-frame UAG
codon. By detecting fluorescence, we can measure the degree to which the OTS is able to
decode the UAG codon in the GFP mRNA and rescue the expression of full-length,
active GFP.
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Figure 2.2. OTS genome integration plasmid schematic. The region flanked by amyE
front and amyE back, outlined by the blue-dashed line, is integrated into the genomic amyE
locus (BSU_03040) upon transformation into B. subtilis. The orthogonal translation system
(expanded below) is made up of two principle components: the orthogonal aminoacyltRNA Synthetase (AcKRS) and its cognate tRNAPyl-opt, each of which is flanked by a
promoter and terminator that was chosen based on a successful gram(+) OTS designed in
(18).

In the years since the initial demonstration of PylRS-tRNAPylCUA, numerous OTS’
derived from the PylRS system have been implemented in several other commonly used
organisms like Saccharomyces cerevisiae (19), Drosophila melanogaster (20), mammalian
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cell lines (21), and mice (22,23). OTSs are powerful tools that afford researchers the
opportunity to introduce unnatural amino acids with unique chemical functional groups at
specific sites in recombinant proteins. Functional groups such as ketomides (24), boronates
(25), and hydroxamates (26) (which are naturally formed via post translational
modification in specific cellular scenarios) are otherwise lacking from the list of functional
groups in the 20 standard amino acids. These functional groups can modulate the activity
of the proteins (24), act as artificial receptors for protein targeting (25), and can even
provide anti-tumour activity in cyclic peptide molecules (26). OTS technology is a
promising avenue to improve the functionality of bio-manufactured proteins and
engineered microorganisms.

2.1.3 Orthogonal translation systems for synthetic auxotrophy.
When working with bacteria, especially those which contain new genetic modifications or
recombinant DNA technologies like OTSs, there are safety and ethical considerations to
address. One such consideration is biocontainment, i.e., the ability to control and or prevent
the growth and release of engineered bacterial strains and potential spread of novel genetic
material in the natural environment.
In controlled laboratory settings, a common and effective means of biocontainment
is the use of auxotrophic strains, which grow if and only if they are provided with a nutrient
that they are unable to synthesize on their own. While effective, this method is only
applicable in settings where the availability of the requisite nutrient can be well controlled
(27). Unfortunately, it is not feasible to control the levels of naturally occurring nutrients
in many of the potential clinical and industrial settings in which live B. subtilis cultures are
used. For example, the work presented here was funded in part through an industrial
partnership with Germiphene Inc, a biomanufacturing company that specializes in
disinfectants and infection control products containing live bacteria. One of Germiphene’s
flagship products (Gobble) contains a live culture of B. subtilis that is used to prevent the
growth of pathogenic bacteria in dental suction lines. The bacteria produce a biofilm that
is safe for human health while also inhibiting the growth of pathogens.
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Unfortunately, Gobble reacts unfavourably in temperate climates by overgrowing
and becoming burdensome to the downstream filtration systems that it is meant to disinfect.
The evacuation systems in which this product is used often contain a plethora of organic
matter which creates optimal conditions for B. subtilis thrive. To prevent the overgrowth
of the active culture, we are developing a bio-contained strain of B. subtilis that requires
the provision of an otherwise unavailable, synthetic nutrient in order to sustain growth.
Though naturally occurring nutrient abundance may not be controllable, the abundance of
synthetic nutrients that are not available in the natural environment can be carefully
monitored and adjusted to achieve a specified growth rate. Accordingly, this project aims
to address the unmet need for a method of B. subtilis biocontainment that can be feasibly
implemented in an environment where naturally occurring nutrient levels cannot be
controlled.
This rationale was similarly articulated in a recent study (27) in which a synthetic
auxotroph strain of E. coli was developed that required supplementation of a non-naturally
occurring (unnatural) amino acid in order to sustain growth. In order to generate the
auxotroph strain, the researchers introduced nonsense TAG mutations in the coding region
of several essential genes (LspA, DnaX, and SecY). Normal decoding of the corresponding
UAG codon in the reading from of an mRNA then leads to prematurely terminated protein.
Because these are essential genes, lack of the complete protein results in growth inhibition.
To rescue growth, the strains were transformed with a plasmid containing an OTS that
could decode the nonsense mutations and rescue translation of the gene transcripts by
incorporating an unnatural amino acid into the nascent peptide.
Recently, Luo (18) reported success in engineering an OTS that functions in a
closely related member of the Bacillus genus, Bacillus cereus. Further, genetic code
expansion by means of an orthogonal translation system was recently achieved in B. subtilis
(28). Taken together, these studies provide precedent indicating that the machinery initially
developed for use in E. coli is both active and orthogonal across a broad range of organisms
and further, that gram (+) bacteria including B. subtilis can tolerate genetic code expansion
using orthogonal translation systems.
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2.1.4 Goals and hypothesis: Developing orthogonal translation for B. subtilis.
Due to its robust molecular characterization and ease of use, it made sense for the initial
development of the OTS to occur in E. coli. But looking forward, the use of these systems
to improve the applications of other industrially relevant bacteria such as B. subtilis is
necessary. Here, I present my work towards developing a plasmid that contains all the
requisite genetic and molecular machinery necessary to pioneer the genetic code expansion
of B. subtilis.
The goal of this project is to develop an orthogonal translation system that functions
in B. subtilis. I hypothesized that co-expressing a pyrrolysyl-tRNA synthetase variant
(AcKRS) in addition to a tRNAPyl-opt gene in B. subtilis would enable reassignment of UAG
codons to incorporate non-standard amino acids, including AcK and BocLys. This
technology could be applied to produce a first-of-its-kind synthetic auxotroph strain of B.
subtilis whose growth would be dependant on the supplementation of an unnatural amino
acid (uAA). Not only would this technology provide a novel means of B. subtilis
biocontainment, it would also grant the organism the ability to produce proteins that contain
unnatural amino acids with novel or enhanced properties (29). By establishing this
technology in B. subtilis, we would develop a strain that could be used for a broad range
of biotechnology applications across both laboratory and clinical settings.
Using the work done in B. cereus (18), I designed an OTS that contains the requisite
genetic components necessary for an orthogonal translation system. The OTS contains two
genes: tRNAPyl-opt which functions to transport the unnatural amino acid AcK to the
ribosome where it then decoded the UAG amber codon present in the mRNA transcript,
and AcKRS, which functions to charge or ligate tRNAPyl-opt with AcK. These two genes
are contained within separate gene cassettes. The expression of tRNAPyl-opt within its gene
cassette is controlled by the promoter and terminator pair that surround the B. subtilis
tRNASer gene (serT). The expression of AcKRS is controlled by the promotor and
terminator pair that surround Staphylococcus aureus sarA gene. The entire system is
contained within a vector (pDR111) that stably integrates the entire OTS into the genome
of B. subtilis at the amyE gene (genomic locus: BSU_03040). Along with the OTS, the
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pDR111 vector also contains a GFP reporter gene that is likewise integrated into the B.
subtilis amyE genomic locus.
Genetic code expansion in B. subtilis offers an innovative solution to the challenges
associated with functional protein production and regulating the growth of an organism in
a system where the availability of naturally occurring nutrients cannot be controlled. Thus,
my work represents the foundational steps towards the development of such a system that
can be implemented in a critical microorganism for synthetic biology applications.

2.2 Methods
2.2.1 Plasmids and bacterial strains
The plasmid pDR111_(Sp)GFP (30) was obtained from the Bacillus Genetic Stock Center
(BGSC ID: ECE278). The vector was next modified for the delivery of the OTS into the
B. subtilis genome. pDR111_(Sp)GFP is a shuttle vector, and as such is capable of
replication in both E. coli and B. subtilis. (Sp)GFP refers to the presence of a variant of
GFP within pDR111 that was codon optimized for expression in Streptococcus
pneumoniae and was found to be optimally active in B. subtilis (30). Any mention of GFP
below refers to the (Sp)GFP variant. While using pDR111_GFP, cloning and mutagenesis
(Section 2.2.3) experiments were conducted in E. coli while GFP expression analysis
(Sections 2.2.6 and 2.2.7) was conducted in B. subtilis.
With assistance from David Wright, we designed the 2.7 kb OTS insert containing
two gene cassettes (Figure 2.2) (sequences are available in Appendix 2.7.2). The first
cassette consisted of a B. subtilis serT promoter/terminator pair and tRNAPyl-opt (12) while
the second cassette consisted of a Staphylococcus aureus sarA promotor/terminator pair
and AcKRS (17) (Figure 2.2). The insert was synthesized in pUC57 (Gene Universal,
Newark, DE, USA). The full sequence is available in Appendix 2.7.2. All work involving
E. coli was conducted with the DH5α strain. All work involving B. subtilis was conducted
using strain 168 (BGSC ID: 1A1).

64
2.2.2 Cloning OTS into pDR111_GFP
Restriction-free cloning (31) was used to insert the 2.7 kb OTS insert into pDR111_GFP.
Primers 1 and 2 (Table 2.1) were used in the primary polymerase chain reaction (PCR) step
to amplify the OTS from the pUC57 vector (used by Gene Universal for shipping
synthesized DNA inserts <5Kb) while simultaneously introducing flanking sequences
which were homologous to pDR111_GFP. The primary PCR was conducted with the
following conditions in a 50 μL PCR reaction volume: 1 × Phusion HF buffer (NEB),
200 μM dNTP (from a 2.5 mM stock solution of equimolar mixed dNTPs (NEB, N0446S)),
500 nM of each primer 1 and 2, 1 U Phusion® polymerase (NEB, Catalog# M0530S), 10
ng of pUC57_OTS template and sterile ddH2O.
The thermocycler protocol had an initial denaturing for 30s at 98°C, then 35 cycles
of; 8s denature at 98°C, 20s anneal at 60°C, 60s extension at 72°C and then followed by a
final extension for 5 min at 72°C. The resulting PCR product was then purified via gel
extraction (Figure S2.1, QIAquick Gel Extraction Kit, Qaigen, product# 28704) and used
as the primer (referred to as a “mega-primer” in the original protocol outlined in (31)) for
a secondary PCR to insert the OTS sequence between flanking regions of pDR111_GFP
that share homology with the B. subtilis AmyE genomic locus (BSU_03040). The
secondary PCR was likewise conducted in a 20 μL PCR reaction: 1 × Phusion HF buffer,
200 μM dNTP, a insert (PCR product from primary PCR):plasmid ratio of 20 ng to 100 ng
of pDR111_GFP was used with 0.4 U Phusion® polymerase. The thermocycler protocol
involving an initial denaturing for 30s at 98°C, then 15 cycles of 8s denature at 98°C, 20s
anneal at 60°C, 5.5min extension at 72°C followed afterwards by a final extension for 6
min at 72°C. Once the secondary PCR was completed, 20 U of DpnI (NEB, R0176S) was
added directly to the reaction mix and incubated for 2 hr at 37°C followed by 20 min at
80°C. 4 ul of the DpnI-treated secondary PCR mix was transformed into E. coli DH5α.
Successful clones were subsequently grow overnight in 5 ml LB and plasmid DNA was
prepped (Geneaid, PDH100) and sequenced (Genewiz, South Plainfield, NJ, USA) using
primers 3-6 to span the entire 2.7 kb OTS insert. Sequencing confirmed the correct location
and orientation of the OTS insert within the pDR111_GFP. A schematic showing the final
pDR111_AcKRS_GFP plasmid map is provided (Figure 2.2).
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2.2.3 Introducing stop codons into GFP
TAG codons were introduced into 2 different permissive sites (S3TAG and E18TAG) in
the coding region of GFP in pDR111_AcKRS_GFP in order to assay the ability of the OTS
to decode stop codons. In total, 3 plasmids were obtained 1) pDR111_AcKRS_GFP, 2)
pDR111_AcKRS_GFP_S3TAG, and 3) pDR111_AcKRS_GFP_E18TAG. The TAG
codons were introduced using a site-directed mutagenesis protocol (32).
Briefly, for each nonsense mutation two 25 μL PCR reactions were conducted
simultaneously, each containing a single primer with the following parameters: PCR mix;
1 × Phusion Buffer, 200μM dNTPs, 40 pmol of a single primer, 500 ng of template DNA,
0.5 U of Phusion Polymerase and sterile ddH2O up to 25 μL Thermocycler protocol: 98°C
for 3min, then 30 cycles of 98°C for 10s, 55°C for 30s, 72°C for 5 min 45s, followed by a
final extension at 72°C for 10min. Once completed, the two reactions were added together,
heated to 95°C and then cooled slowly as follows; 95°C for 5min, 90°C for 1min, 80°C for
1min, 70°C for 30s, 60°C for 30s, 50°C for 30s, 40°C for 30s and finally held at 37°C. 20
U of DpnI was then added to the cooled PCR reaction which was then incubated overnight
at 37°C. The next day, 4 uL of the DpnI-treated product was transformed into E. coli DH5α
cells. Plasmid DNA from successful colonies was purified (Geneaid, PDH100) and
sequenced with primer 7 (Table 2.1) to confirm the presence and location of the TAG
mutations. Primers 8 and 9 were used to replace the TCT codon (serine) at position 3 with
TAG, while primers 10 and 11 were used to replace the GAA codon (glutamic acid) at
position 18 with TAG.

2.2.4 B. subtilis competence induction.
B. subtilis minimal media included minimal salts solution (5x) per litre: (NH4)2SO4, 10.0
g; K2HPO4, 74 g; KH2PO4, 27.0 g; trisodium citrate, 9.5 g; MgSO4 7 H2O, 1.0 g; pH 7.0;
glucose 20% (w/v) solution; casamino acids 2% (w/v) solution. Minimal‐ growth medium
per 100 ml: 20 ml minimal salts (5x); 2.5 ml glucose 20% (w/v) solution; 1 ml casamino
acids; 20 μg/ml L-tryptophan. Starvation medium per 100 ml: 20 ml minimal salts; 2.5 mL
glucose 20% (w/v) solution.
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Competent cell preparation: On day one, B. subtilis 168 stock from BGSC was
received as a filter disk inoculated with bacterial culture. The filter disk was aseptically
transferred to a standard LB agar plate. Then, 500 μL of sterile LB was added on top of the
filter disk and the plate was swirled gently to allow the culture to disperse across the plate.
The plate was then incubated overnight at 37°C to allow colony growth. Day two, 10 ml of
minimal growth medium in a 100 ml flask was inoculated with cells from a single colony
and incubated (37°C) overnight (~16‐ 18 hours) with agitation. Day three, 1.4 ml of
overnight culture was added to 10 ml of pre‐ warmed fresh minimal growth medium in a
100 ml flask. This sample was grown for 3 hours at 37°C with agitation. Then 11 ml of
starvation medium was added, and the culture continued to grow for 2 hours at 37°C with
agitation. At this point the culture was maximally competent (33), and 0.5 ml samples were
frozen in 10% glycerol (v/v) at -80°C.
2.2.5 B. subtilis transformation
An aliquot of the competent 168 cells (Section 2.2.5) was thawed quickly in a 37°C water
bath. To this thawed sample, 500-1000 ng of plasmid DNA was added and mixed with
gentle pipetting. The cells were then incubated for 25 minutes at 37°C in with agitation.
Then, 500 μL of LB medium was added and the cells were further incubated for 1.5 hours
at 37°C with shaking to allow for the expression of antibiotic markers. After this
incubation, cells were pelleted (5000

g for 10 min), supernatant was removed, and the

pellet was resuspended in 200 μL of fresh LB. 100 μL of this sample was then plated on
LB agar containing selective antibiotics. For transformations using the pDR111 vector, 100
μg/ml of spectinomycin was required for selection. Transformants appeared following
overnight incubation at 37°C. An aliquot of competent 168 cells was transformed with
pDR111_GFP and the following day (20 hours post-transformation) transformants were
imaged using a BioRad ChemiDoc imager to detect GFP fluorescence to confirm
transformation of the entire pDR111_GFP plasmid (Figure S2.2). BioRad ChemiDoc
imager settings for detection of GFP fluorescence; Filter: 530/38 nm, Light: Blue Epi
illumination.
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2.2.6 Integration-detection assays
pDR111_AcKRS_GFP contains two regions of DNA sequence that are homologous to the
B. subtilis amyE gene (genomic locus: BSU_03040). Upon transformation, these regions
of homology are integrated, along with the DNA in between them (Figure 2.2) into the B.
subtilis genome at the amyE site. amyE encodes alpha-amylase, a protein which is not
essential for growth but is required to metabolize starch. When pDR111_AcKRS_GFP
integrates into the B. subtilis genome, the amyE gene is disrupted and starch metabolism is
abolished. The loss of starch metabolism can be detected using a colorimetric iodinestaining assay as a proxy for the disruption of the amyE gene due to successful integration.
B. subtilis is transformed as described in Section 2.2.5 on LB agar plates containing
spectinomycin (100 μg/ml) that were supplemented with soluble starch powder (1% w/v)
and incubated overnight at 37°C. To detect starch metabolism the following day, the plates
containing successful transformants are flooded with 1 ml Gram’s iodine stain
(ThermoFisher, R40056) and transformants are observed for the presence of dye-free halos.
A dye-free halo surrounding a colony indicates starch hydrolysis by the organism due to
extracellular starch metabolism enzymes, i.e., alpha-amylase. Colonies that do not have
dye-free halos surrounding them are unable to metabolize starch and are likely to contain
the integrated DNA from the pDR111_AcKRS_GFP plasmid at their disrupted amyE
locus.
Colonies that lack dye-free halos were then subjected to a PCR screen using primer
pairs 12-13 and 14-15 which are designed to amplify the junctions (12, 13: upstream, 14,
15: downstream) between the genomic amyE locus and integrated region of
pDR111_AcKRS_GFP in cases where pDR111_AcKRS_GFP integration into amyE was
successful. Colony PCR screen protocol: 50 μl PCR reaction (1 × Phusion® HF buffer,
200 μM dNTP, 500 nM of each primer (either 12 and 13 or 14 and 15), 1 U Phusion®
polymerase (NEB, Catalog# M0530S), sterile ddH 2O up to 50 μL. Template DNA which
was obtained as follows: The 50 μL PCR-reaction mixture was inoculated with B. subtilis
cells picked from a transformant colony. The cells were boiled for 5 min (98°C) in sterile
ddH20 to release DNA during the first step of the PCR reaction. The thermocycler protocol
was as follows: 5 min at 98°C (to release/denature DNA from transformed B. subtilis cells),
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then 35 cycles of; 8s denature at 98°C, 20s anneal at 67°C, 60s extension at 72°C and then
followed by a final extension for 5 min at 72°C.
2.2.7 Fluorescence measurements
For quantitative fluorescent measurements, a microplate-reader was used following the
protocol established in (30). Briefly, LB medium with 100 μg/ml spectinomycin and 10
mM Nε-acetyl-L-lysine (AcK) was inoculated with a B. subtilis colony that was
transformed

with

a

pDR111_AcKRS_GFP,

GFP-bearing

pDR111

pDR111_GFP_S3TAG,

plasmid

(either

pDR111_GFP,

pDR111_AcKRS_GFP_S3TAG,

pDR111_GFP_E18TAG pDR111_AcKRS_GFP_E18TAG, see section 2.2.3) and grown
overnight at 37°C with agitation. Biological triplicate cultures started from independent
colonies were maintained for each condition.
The next day, the cultures were aliquoted into 4 different LB growth medias that
were supplement as follows: 1) 100 μg/ml spectinomycin, no AcK, no isopropyl-β-D-1thiogalactopyranoside (IPTG); 2) 100 μg/ml spectinomycin, 10 mM AcK, no IPTG, 3. 100
μg/ml spectinomycin, no AcK, 0.1 mM IPTG; 4) 100 μg/ml spectinomycin, 10 mM AcK,
0.1mM IPTG. Each culture was diluted to an OD600 = 0.1 in 5 ml of the above-mentioned
media. A negative control culture of untransformed WT B. subtilis 168 was also prepared
following the same growth conditions above but in the absence of spectinomycin, AcK or
IPTG. The next day, 200 μL aliquots of each culture were added to wells of a 96-well
microtiter plate and fluorescence and OD600 values were detected using a Synergy H1
Hybrid microplate reader (BioTek, Agilent), GFP signals were detected using an excitation
wavelength at 485nm [20-nm width] and emission at 535 nm [25-nm width]. Relative GFP
levels of each culture compared to the negative control untransformed WT B. subtilis 168
and determined as follows. Background values for turbidity (OD600) and fluorescence were
taken (based on 3 biological replicates) from untransformed (WT) B. subtilis control
culture grown similarly as above. The respective averages of these background values were
subtracted from the optical density and fluorescence reading taken of each culture
containing a GFP variant. In order to account for potential differences in growth, final
background-corrected fluorescence measurements were normalized by OD600.
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Table 2.1. Primers used in this study.

Primer
Sequence
TCTTTTCTTTTCCAGACCTGAGGGAGGCGGCTCGA
1

Description
pDR111_site3_fwd

2

pDR111_site3_rev

3
4
5
6
7
8
9
10
11
12
13
14
15

GACTAGTAAGATTATGATCTTCTGAACG
TGGCTTTTCCCCGGGAACCTCACACCATTTCT
CGAGCTGCAGAGTGCCATTAG
GGATCATCCGTTTAGGCTGG

pDR111_site3
_seqver_fwd
CGAGCAAGATGCATCAAATAGGGAGG
OTS_F2
ATCGCCGCAAGCCATTTCG
OTS_R2
ATCTATTGACCGCAGTGATAGCC
pDR111_site3
_seqver_rev
AATCAAGACGTCTTATTTATACAATTCATCCATACCATG GFP_Rev
CAAACATGGTTTAGAAAGGTGAAGAATTG
Fwd: S3F
CAATTCTTCACCTTTCTAAACCATGTTTG
Rev: S3R
CATCACCATCCAACTAAACCAAAATTGG
Fwd: E18F
CCAATTTTGGTTTAGTTGGATGGTGATG
Rev: E18R
CGGCTGCGAGTGCTGAAAC
Int_ver_fwd1
GTTTCGGTGATGAAGATCTTCCCG
Int_ver_rev1
GGATCATCCGTTTAGGCTGGG
Int_ver_fwd3
CATCCTTAAACGCCTGTCGTC
Int_ver_rev3

2.3 Results
2.3.1 Designing a plasmid to integrate the Orthogonal Translation System (OTS) into
the B. subtilis genome
pDR111_AcKRS_GFP is a 11.6 kb plasmid (Figure 2.2), derived from pDR111_GFP (30).
The plasmid contains the OTS necessary to decode and reassign the UAG codon to
incorporate AcK into proteins. Within the original pDR111_GFP (8.8 kb), there is a 4.2 kb
region of DNA that is integrated into the B. subtilis genome upon transformation.
Integration occurs via a double crossover event between the B. subtilis genome and
sequences flanking the 4.2 kb region which share homology to the B. subtilis amyE gene
(34). This 4.2 kb region also contains a copy of GFP that has been optimized for expression
within B. subtilis (30) under the control of lacI that will serve as an assay for UAGreadthrough. The OTS itself, is a 2.8 kb sequence that contains the orthogonal tRNA
(tRNAPyl-opt) and aminoacyl-tRNA synthetase (AcKRS) pair. I also designed in 4 mutations
(V31I, T56P, H62Y, and A100E; IPYE) to the sequence of AcKRS that were introduced
to mirror those discovered by Bryson et al. (17) that improve the efficiency of the PylRS

70
system and increased the yield of proteins containing unnatural amino acids by up to 10fold.
To promote expression of the tRNAPyl-opt and AcKRS genes, the OTS insert
contained two gene cassettes (all sequences are available in Appendix 2.7.2). The first
cassette contained tRNAPyl-opt, the expression of which was controlled by the flanking B.
subtilis serT promoter/terminator pair. The second cassette contained AcKRS, the
expression of which was controlled by the flanking Staphylococcus aureus sarA
promotor/terminator pair (Figure 2.2). The chosen serT promotor/terminator pair for
tRNAPyl-opt, and sarA promotor/terminator pair for AcKRS were previously determined to
be effective for the expression of these components in a related gram (+) bacterium,
Bacillus cereus (18).
The 2.8 kb OTS, as described above (Appendix 2.7.2 for sequence), was
synthesized by Gene Universal (pUC57_OTS) (Newark, DE, USA) and cloned (Section
2.2.2) into the 4.2 kb genome integration region of the pDR111_GFP plasmid (Section
2.2.3) to yield the final OTS construct: pDR111_AcKRS_GFP (Figure 2.2). This version
of the construct contains a wild type and positive control version of GFP that will express
and fluoresce upon IPTG induction without the need for OTS function. Subsequently,
nonsense TAG mutations were inserted at 2 permissive sites in the coding region of GFP
(S3TAG and E18TAG). These nonsense mutations will prevent full-length translation of
GFP from occurring unless the OTS is able to decode the UAG codon and incorporate AcK
into the growing peptide chain.

2.3.2 Assessing integration of pDR111_AcKRS_GFP into the B. subtilis amyE locus
I obtained B. subtilis strain 168 from the BGSC (BGSC I.D. 1A1) and made competent cell
stocks using a protocol from the original paper that described B. subtilis transformation by
Anagnostopoulos and Spizizen in 1961 (33) (Section 2.2.4). Traditional antibiotic selection
with spectinomycin was used to isolate colonies which had successfully taken up the
pDR111_AcKRS_GFP plasmid but further assessment was necessary to ensure that the
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plasmid had integrated into the B. subtilis genome and that this integration had occurred at
the correct locus.
An initial colorimetric (starch-iodine) screen was used to identify colonies that
lacked alpha-amylase activity (starch metabolism) as a proxy assessment for the disruption
of the amyE gene due to pDR111_AcKRS_GFP integration at the amyE locus. The results
of this colorimetric assay are displayed in Figure 2.3. The absence of dye-free halos
surrounding the B. subtilis colonies transformed with pDR111_AcKRS_GFP (Figure 2.3B)
indicate that these bacteria are unable to digest the soluble starch present in the agar (1%
starch w/v).
Final confirmation of proper integration was determined by PCR-screening (Figure
2.4). The PCR reaction used primers 12-13 (Figure 2.4 lane 2) and 14-15 (Figure 2.4 lane
3) to amplify 3 kb and 3.2 kb regions of the upstream and downstream junctions
(respectively) that are created when pDR111_AcKRS_GFP is properly integrated into the
genomic amyE locus of B. subtilis. The results of a positive control PCR reaction using
primers 12-13 and pDR111_AcKRS_GFP as the DNA template is shown in lane 5.
2.3.3 Assaying OTS function by means of TAG decoding and GFP fluorescence rescue
Previously, AcK-dependant GFP fluorescence in response to UAG nonsense mutations
within the GFP gene was achieved using the tRNAPyl-opt and AcKRS pair in E. coli (13). A
similar AcK-dependant GFP fluorescence system was employed here to assess the degree
to which the OTS was able to decode UAG codons and rescue expression of GFP in B.
subtilis.
Figure 2.5 contains the results of a 96-well micro plate assay conducted using a
Synergy H1 microplate reader to detect GFP fluorescence in live cultures of B. subtilis that
have been transformed with 1 of 6 pDR111_GFP plasmid variants or that remain
untransformed (negative control). All 6 of the transformed B. subtilis cultures (each
transformed with a different pDR111_GFP variant) were grown in 4 different media
conditions: 1) no AcK, no IPTG, 2) 10 mM AcK, no IPTG; 3) no AcK, 0.1mM IPTG; or
4) 10 mM AcK, 0.1mM IPTG. Figure 2.5 contains the fluorescence data collected from
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each of the overnight cultures presented as fluorescence intensity: measured fluorescence
value/OD600 (arbitrary units, AU).

A

B

pHT_(Sp)GFP
replicating plasmid

pDR111_acKRS_GFP
integrative plasmid

Figure 2.3. Colorimetric assay of integration within the B. subtilis amyE locus. Both
plates contain 1% (w/v) soluble starch powder and were flooded with saturating amounts
of Gram’s iodine. The left plate (A) contains B. subtilis 168 (BGSC ID: 1A1) colonies that
have been transformed with pDR111_AcKRS_GFP. The lack of dye-free halos
surrounding the colonies in (A) is indicative of a loss of starch metabolism. The right plate
(B) contains B. subtilis 168 (BGSC ID: 1A1) colonies that have been transformed with
pHT_(Sp)GFP, a non-integrative and replicating plasmid that does not disrupt starch
metabolism as indicated by the presence of white, dye-free (starch-free) halos surrounding
the transformed colonies.
L

1

2

3

4

5

3 kb

Figure 2.4. PCR-screen of B. subtilis colonies with integrated OTS. Lanes 1 and 2 used
primers 12 and 13 to amplify the upstream junction of amyE-pDR111_AcKRS_GFP. Lane
1 used WT 168 bacterial cells as its source of template DNA and lane B used 168 cells that
had been transformed with pDR111_AcKRS_GFP. Lanes 3 and 4 used primers 14 and 15
to amplify the downstream junction of amyE-pDR111_AcKRS_GFP. Lane 3 used 168
cells that had been transformed with pDR111_AcKRS_GFP as its source of template DNA
and lane 4 used WT 168 bacterial cells. The positive control lane denoted with (lane 5)
used (30ng) purified pDR111_AcKRS_OTS plasmid as the template DNA for the reaction
with primers 12 and 13.
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Of the 25 conditions tested, only 4 cultures had significantly increased levels of
GFP fluorescence compared to the untransformed negative control culture based on a oneway

ANOVA

test.

B.

subtilis

transformed

with

either

pDR111_GFP

or

pDR111_AckRS_GFP, grown with IPTG and with or without AcK all contained
significant fluorescence intensity (p < 0.0001) As expected, the presence or absence of
AcK did not significantly affect the level of GFP fluorescence in B. subtilis transformed
with pDR111_GFP or pDR111_ACK_GFP. Similarly, the addition of the OTS to the
pDR111_GFP plasmid (pDR111_GFP vs pDR111_AcKRS_GFP) did not significantly
affect the level of GFP fluorescence observed, regardless of the media. The lack of change
in fluorescence values for cultures transformed with WT GFP is to be expected as the
expression of these GFP variants is solely dependant on IPTG induction and not the
functionality of the OTS. None of the cultures containing a GFP gene with a nonsense
mutation (at either of the permissive sites S3 or E18) displayed any significant GFP
fluorescence regardless of the presence or absence of the OTS, AcK or IPTG.
2.4 Discussion
2.4.1 Progress and next steps for expanding the genetic code of B. subtilis
In this chapter, I described the conceptualization, construction and initial testing of an
orthogonal translation system designed to decode UAG codons. I stably integrated the
OTS and GFP reporter variants into the genome of B. subtilis. The design of the system
was centered around the newly improved (12,13,17), highly efficient, and broadly active
orthogonal tRNAPyl-opt and AcKRS pair (12). Genetic code expansion using similar
orthogonal tRNA synthetase-tRNA pairs has been implemented in a number of important
model organisms (19-21) including other members of the Bacillus genus (18). The system
developed here is the first of its kind reported for B. subtilis.
The construction of the preliminary OTS along with its stable integration into the
B. subtilis genome has been accomplished here, however, demonstration of the system’s
ability to decode UAG codons and incorporate AcK has not yet been achieved. Going
forward, there are several avenues to explore in order to achieve OTS-mediated UAG
decoding in B. subtilis using the system designed and developed here. The first step towards
this goal would be to determine the aspect(s) of the system that are not functioning
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properly. PCR-screens and sequencing have given us confidence that the system’s genomic
location, sequence integrity and ability to express wildtype GFP are satisfactory.
Sequencing has confirmed that the intended TAG mutations are confined to their intended
permissive locations and previous studies have demonstrated that these positions in GFP
are permissible for unnatural amino acid insertion (35).

Figure 2.5. Fluorescence quantification of GFP and GFP variants bearing nonsense
mutations in B. subtilis. GFP fluorescence intensities of live cultures of B. subtilis
represent each culture’s fluorescence data/OD600 of that culture. Cultures were either
transformed with 1 of 6 pDR111_GFP plasmid variants (containing either GFP, GFP
(S3TAG), or GFP (E18TAG) with or without AcKRS), or in the case of the WT negative
control, remained untransformed as indicated below each bar. All 6 of the transformed B.
subtilis cultures were aliquoted and grown in 4 different media conditions containing
neither, either, or both of 10 mM AcK and 0.1 mM IPTG. The type of GFP, presence or
absence of AcKRS and media supplement conditions of each culture are indicated below
each data bar. Of the 25 conditions tested, only 4 cultures had significantly increased levels
of GFP fluorescence (denoted by star above data bar) compared to the untransformed
negative control WT culture based on a one-way ANOVA: pDR111_GFP (AcK-/IPTG+):
p < 0.0001, pDR111_GFP (AcK+/IPTG+): p < 0.0001, pDR111_AckRS_GFP (AcK/IPTG+): p < 0.0001 and pDR111_AcKRS_GFP (AcK+/IPTG+), p < 0.0001. Each
condition was completed in triplicate (n=3), the height of the bars indicate the mean value
of the three replicates and the individual values that contribute to the means are shown as
circles surrounding the mean. Error bars represent 1 standard deviation above and below
the mean.
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Further, the functionality of the tRNAPyl-opt-AcKRS pair, along with the ability to
make use of unnatural amino acid derivatives of lysine (including, but not limited to, AcK)
has been demonstrated in the closely related B. cereus (18) and so, while not confirmed by
my own work, it is less likely that these components are incompatible with B. subtilis and
is instead more likely that they are not being properly expressed. The problem may stem
from insufficient expression of either (or both) of the tRNAPyl-opt or AcKRS components
of the system due to suboptimal activity of their respective promoters. In the absence of an
available antibody with which to test the expression of AcKRS directly, I would next add
a co-translationally cleavable mCherry tag to the N-terminus of AcKRS to monitor its
expression via fluorescence and confirm via western blotting using available anti-mCherry
antibodies. This approach was successfully implemented to detect the expression of PylRS
in primary tissue collected from rat neocortex (23).
To test for issues related to insufficient expression of the OTS components, I could
replace the current promoter and terminator pairs (sarA for AcKRS and serT for tRNAPylopt

). As part of the design of our OTS, unique restriction enzyme cut sites were incorporated

in between each component (sarA promoter, AcKRS, sarA terminator, serT promoter,
tRNAPyl-opt, serT terminator) of the system to facilitate the exchange of components if
necessary. Using these sites to our advantage, I would systematically replace and test a
series of 5 different promotor/terminator pairs (P srf (36), Pxyl (37), PgsiB (38), Pxyl (39), and
PHpaII (40)) that all have well established expression capabilities within B. subtilis.

2.4.2 Previous work involving an expanded genetic code in B. subtilis.
As mentioned previously (Section 2.1.3), genetic code expansion by means of recoding the
UAG stop codon to code for unnatural amino acids using orthogonal translation systems
has been previously established in B. cereus, a member of the Bacillus genus that is closely
related to B. subtilis (18). However, this was not the first time that a member of the Bacillus
genus had been the subject of research concerning the engineering the genetic code. In
1983, Wong (41) demonstrated that a Trp auxotroph strain of B. subtilis could become
dependant instead on a Trp analog: 4-fluorotryptophan (4-FTrp). After several rounds of
selection and nitrosoguanidine-mediated mutagenesis on media containing increasing
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amounts of 4-FTrp and decreasing amounts of Trp, Wong and co-workers were able to
isolate a strain that could grow on agar supplemented with only 4-FTrp in place of Trp. In
the evolved strain, Trp supplementation could still rescue growth, but to a reduced degree
compared to the original parent strain. Effectively, Wong had isolated the first ever
synthetic auxotroph strain of B. subtilis within which all codons that once coded for Trp
now coded for the unnatural amino acid 4-FTrp. These results demonstrate that the
translation machinery of B. subtilis is tolerant and capable of utilizing unnatural amino
acids for protein production.

2.4.3 Orthogonal translation systems within the Bacillus genus
More recently, the focus of molecular technologies that expand the genetic code have
focused primarily on utilizing codons that are not already assigned to one of the twenty
canonical amino acids, i.e., the stop codons. Of the 3 stop codons, UAG is the least
frequently used stop codon in the genomes of a wide array of organisms including E. coli
and B. subtilis (42), which makes UAG the most suitable to reassignment. Indeed, in their
2016 study on genetic code expansion in B. cereus, Luo et al. made use of a single plasmid
system that contained the requisite molecular machinery to decode the UAG codon with
Nε-(tertbutoxycarbonyl)-L-lysine (18). The authors investigated a class of molecules
known as thiopeptides: a subclass of ribosomally synthesized and post translationally
modified cyclic peptides that have promising antibiotic (43) and antitumor (44) properties.
Using their OTS, they were able to achieve increased yields of purified active thiopeptides
by incorporating photo-caged amino acids that provide protection from post translational
modifications that naturally inactivate the compounds. These photo caged residues could
then be removed post-purification to yield active products. This is but one example of a
generalizable scenario in which the expansion of the protein chemistries available in novel
bacterial hosts can improve the production of medically relevant or bio-manufacturable
molecules.
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2.4.4 Significance of orthogonal translation in the B. subtilis system
There are circumstances in which the production of sought-after bio-manufactured
molecules can be improved by means of orthogonal translation systems. As this practice
inevitably becomes more commonplace, there will be a demand for its use in the
manufacturing of products in the food or medical industries, intended for human contact or
consumption.
In the domain of biomanufacturing, B. subtilis is favoured over other common
biochemical ‘work horses’ like E. coli because of its lack of lipopolysaccharides (LPS).
The LPS-derived endotoxins contained in the cell wall of E. coli necessitates additional
purifications of any E. coli-derived products that are intended for human contact or
consumption. These extra steps can be detrimental to the final yield and overall costs
associated with E. coli-based biomanufacturing systems (45). Furthermore, the ease of final
product purification from B. subtilis is superior to E. coli due to its proficiency at secreting
endogenous or recombinant enzymes into its growth media (45,46). In some cases, the
secretion of protein-products into the extracellular environment can facilitate proper
folding if the reducing environment of the cytoplasm is incompatible with the native
conditions of the given recombinant protein (47).
Aside from designer protein production, the development of an OTS for B. subtilis
is an important step towards a novel approach to biocontainment or growth control.
Previous examples of synthetic auxotroph bacterial strains have been developed using
orthogonal translation systems to ‘addict’ E. coli to amino acids that do not occur in nature
(27). Such strains boast nearly undetectable levels of escape mutations (27), making this
method of biocontainment particularly intriguing. By introducing this method of
biocontainment to an organism that already possesses the GRAS-status, we would develop
a strain with an exceptionally large range of potentially applications. Such a strain would
be applicable for use in a system where the risk of potential contact with humans has
precluded the use of other, potentially pathogenic bacteria like E. coli. For example, in the
case of dental evacuation system cleaners (such as Gobble from Germiphene, Inc) that use
live cultures of bacteria to disinfect the accompanying plumbing system. To remain
efficient, such a system requires the ability to control the growth of the active culture (such
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that it does not overgrow to the point of becoming burdensome to the system) despite the
plethora of nutrients present in the form of the organic material present within patient’s
saliva. A bio-contained, synthetic auxotroph strain of B. subtilis that is dependant on the
provision of an unnatural amino acid not found in organic material would meet the
specifications of such a situation. In conclusion, this chapter represents critical first steps
toward the expansion of the genetic code of B. subtilis for applications in infection control
and bio-manufacturing.
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2.7 Appendix 2
2.7.1 Supplementary figures.

Figure S2.1 DNA Gel image showing the progress and results of the restriction free
cloning method used to insert the OTS into pDR111_GFP. A) Restriction free cloning
primers pDR111_site3_fwd and pDR111_site3_rev (Table 2.1) were used to amplify the
AcKRS OTS (see Section 2.7.2) from the pUC57 vector in which the sequence was
delivered (Genewiz, South Plainfield, NJ, USA). PCR reaction protocol is outlined in
Methods (see Section 2.2.2). The three lanes represent 3 replicates of the same reaction.
The major band, denoted with the black arrowhead, just below the 3 kb marker of the ladder
corresponds to the intended AcKRS OTS product (2759 bp). These 3 bands were extracted
and the DNA within was used as a primer in the secondary PCR reaction (Section 2.2.2) to
insert the AcKRS OTS into pDR111_GFP. B) A PCR screen (Section 2.2.6) was conducted
on E. coli colonies that were transformed with the final restriction free cloning product
(Section 2.2.2). The lane denoted by (+) was the positive control screen that used
pUC57_AcKRS as a template instead of bacterial cells. Lanes 1-8 represent colonies
screened. Underlined lanes (2, 3, and 8) were positive, indicated by the presence of a bar
at the expected AcKRS band size (2759 bp). Plasmid DNA was prepped from these
colonies, sequenced, and found to contain pDR111_AcKRS_GFP.
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Figure S2.2. Successful transformation and GFP expression in B. subtilis. Competent
cell preparations of B. subtilis 168 were plated and treated as follows: i) a stock of
competent B. subtilis was diluted and plated directly onto LB agar supplemented with 0.1
mM IPTG and no antibiotics, ii) a stock of competent B. subtilis was diluted and plated
directly onto LB agar supplemented with 0.1 mM IPTG and 100 μg/ml spectinomycin, iii)
a stock of competent B. subtilis was transformed with pDR111_AckRS_GFP and plated
on LB agar supplemented with 0.1 mM IPTG and 100 μg/ml spectinomycin. BioRad
ChemiDoc imager settings for A: Filter: None, Light: White Trans illumination, White
Light Conversion Screen, and for B: Filter: 530/38 nm, Light: Blue Epi illumination.
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2.7.2 Sequences of plasmids and genes
Complete pDR111_AcKRS_GFP (11599 bp)
AACAAAATTCTCCAGTCTTCACATCGGTTTGAAAGGAGGAAGCGGAAGAATGAAGTAAGA
GGGATTTTTGACTCCGAAGTAAGTCTTCAAAAAATCAAATAAGGAGTGTCAAGAATGTTT
GCAAAACGATTCAAAACCTCTTTACTGCCGTTATTCGCTGGATTTTTATTGCTGTTTCAT
TTGGTTCTGGCAGGACCGGCGGCTGCGAGTGCTGAAACGGCGAACAAATCGAATGAGCTT
ACAGCACCGTCGATCAAAAGCGGAACCATTCTTCATGCATGGAATTGGTCGTTCAATACG
TTAAAACACAATATGAAGGATATTCATGATGCAGGATATACAGCCATTCAGACATCTCCG
ATTAACCAAGTAAAGGAAGGGAATCAAGGAGATAAAAGCATGTCGAACTGGTACTGGCTG
TATCAGCCGACATCGTATCAAATTGGCAACCGTTACTTAGGTACTGAACAAGAATTTAAA
GAAATGTGTGCAGCCGCTGAAGAATATGGCATAAAGGTCATTGTTGACGCGGTCATCAAT
CATACCACCAGTGATTATGCCGCGATTTCCAATGAGGTTAAGAGTATTCCAAACTGGACA
CATGGAAACACACAAATTAAAAACTGGTCTGATCGAAATAGTACATAATGGATTTCCTTA
CGCGAAATACGGGCAGACATGGCCTGCCCGGTTATTATTATTTTTGACACCAGACCAACT
GGTAATGGTAGCGACCGGCGCTCAGGATCCTAACTCACATTAATTGCGTTGCGCTCACTG
CCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCG
GGGAGAGGCGGTTTGCGTATTGGGCGCCAGGGTGGTTTTTCTTTTCACCAGTGAGACGGG
CAACAGCTGATTGCCCTTCACCGCCTGGCCCTGAGAGAGTTGCAGCAAGCGGTCCACGCT
GGTTTGCCCCAGCAGGCGAAAATCCTGTTTGATGGTGGTTGACGGCGGGATATAACATGA
GCTGTCTTCGGTATCGTCGTATCCCACTACCGAGATATCCGCACCAACGCGCAGCCCGGA
CTCGGTAATGGCGCGCATTGCGCCCAGCGCCATCTGATCGTTGGCAACCAGCATCGCAGT
GGGAACGATGCCCTCATTCAGCATTTGCATGGTTTGTTGAAAACCGGACATGGCACTCCA
GTCGCCTTCCCGTTCCGCTATCGGCTGAATTTGATTGCGAGTGAGATATTTATGCCAGCC
AGCCAGACGCAGACGCGCCGAGACAGAACTTAATGGGCCCGCTAACAGCGCGATTTGCTG
GTGACCCAATGCGACCAGATGCTCCACGCCCAGTCGCGTACCGTCTTCATGGGAGAAAAT
AATACTGTTGATGGGTGTCTGGTCAGAGACATCAAGAAATAACGCCGGAACATTAGTGCA
GGCAGCTTCCACAGCAATGGCATCCTGGTCATCCAGCGGATAGTTAATGATCAGCCCACT
GACGCGTTGCGCGAGAAGATTGTGCACCGCCGCTTTACAGGCTTCGACGCCGCTTCGTTC
TACCATCGACACCACCACGCTGGCACCCAGTTGATCGGCGCGAGATTTAATCGCCGCGAC
AATTTGCGACGGCGCGTGCAGGGCCAGACTGGAGGTGGCAACGCCAATCAGCAACGACTG
TTTGCCCGCCAGTTGTTGTGCCACGCGGTTGGGAATGTAATTCAGCTCCGCCATCGCCGC
TTCCACTTTTTCCCGCGTTTTCGCAGAAACGTGGCTGGCCTGGTTCACCACGCGGGAAAC
GGTCTGATAAGAGACACCGGCATACTCTGCGACATCGTATAACGTTACTGGTTTCATCAA
AATCGTCTCCCTCCGTTTGAATATTTGATTGATCGTAACCAGATGAAGCACTCTTTCCAC
TATCCCTACAGTGTTATGGCTTGAACAATCACGAAACAATAATTGGTACGTACGATCTTT
CAGCCGACTCAAACATCAAATCTTACAAATGTAGTCTTTGAAAGTATTACATATGTAAGA
TTTAAATGCAACCGTTTTTTCGGAAGGAAATGATGACCTCGTTTCCACCGAATTAGCTTG
CATGCAAAGAATCTTGCTTGGCAAGGTTCTTTTTTTTGTCTTTTCAAAAAAGCACGAAAA
AAGCACCCATAAGGTAAACTTTTGAGTGCTTTGCTATAAATACGCTTCACAGTTTCTTCT
TCATTTTTAACAAACAAAAAACCCAGCTCATTGAGCTGGGTTTAAGCTGGCTTGGCGGCG
TCCTAGTACTGCAGAATTGCCGACCTTGACTAGTGCTCATTATTATTTATACAATTCATC
CATACCATGTGTAATACCAGCAGCTGTAACAAATTCCAACAAAACCATGTGATCACGTTT
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TTCATTTGGATCTTTAGACAATTTAGATTGTGTAGACAAATAATGATTATCTGGCAACAA
AACTGGACCATCACCAATTGGTGTATTTTGTTGATAATGATCAGCCAATTGAACAGAACC
ATCTTCAATATTATGACGAATTTTAAAATTAACTTTAATACCGTTCTTTTGTTTATCAGC
CATGATATAAACATTATGAGAATTATAATTATATTCCAATTTATGACCCAAGATATTACC
ATCTTCTTTAAAATCGATACCCTTCAATTCGATACGATTAACCAATGTATCACCTTCAAA
CTTAACCTCAGCACGTGTCTTATAATTACCATCATCCTTGAAAAAGATTGTACGTTCTTG
AACATAACCTTCTGGCATAGCAGATTTAAAGAAATCATGTTGTTTCATGTGATCTGGATA
ACGAGCAAAACATTGCAAACCATAAGCAAATGTTGTAACCAATGTTGGCCAAGGAACTGG
CAATTTACCAGTTGTACAAATAAATTTCAATGTCAATTTACCGTATGTAGCATCACCTTC
ACCTTCACCAGAAACAGAAAATTTATGACCATTAACATCACCATCCAATTCAACCAAAAT
TGGAACAACACCTGTAAACAATTCTTCACCTTTAGAAACCATGTTTGTCCTCCTTATTAG
TTAATCAGCTAGCTGTCGACTAAGCTTAATTGTTATCCGCTCACAATTACACACATTATG
CCACACCTTGTAGATAAAGTCAACAACTTTTGCAAAATGAATTGTGAGTGCTCACATTTA
CCCTCGAGCAACGTTCTTGCCATTGCTGCATAAAAAACGCCCGGCGGCAACCGAGCGTTC
TGAATTAATTAATCATCGGGAAGATCTTCATCACCGAAACGCGGCAGGCAGCTCTAGAGT
TAACAAGAGTTTGTAGAAACGCAAAAAGGCCATCCGTCAGGATGGCCTTCTGCTTAGCTA
GAGCGGCGGATTTGTCCTACTCAGGAGAGCGTTCACCGACAAACAACAGATAAAACGAAA
GGCCCAGTCTTTCGACTGAGCCTTTCGTTTTATTTGATGCCTCAAGCTAGAGAGTCGAAT
TCCTGCAGCCCTGGCGAATGGCGATTTTCGTTCGTGAATACATGTTATAATAACTATAAC
TAATAACGTAACGTGACTGGCAAGAGATATTTTTAAAACAATGAATAGGTTTACACTTAC
TTTAGTTTTATGGAAATGAAAGATCATATCATATATAATCTAGAATAAAATTAACTAAAA
TAATTATTATCTAGATAAAAAATTTAGAAGCCAATGAAATCTATAAATAAACTAAATTAA
GTTTATTTAATTAACAACTATGGATATAAAATAGGTACTAATCAAAATAGTGAGGAGGAT
ATATTTGAATACATACGAACAAATTAATAAAGTGAAAAAAATACTTCGGAAACATTTAAA
AAATAACCTTATTGGTACTTACATGTTTGGATCAGGAGTTGAGAGTGGACTAAAACCAAA
TAGTGATCTTGACTTTTTAGTCGTCGTATCTGAACCATTGACAGATCAAAGTAAAGAAAT
ACTTATACAAAAAATTAGACCTATTTCAAAAAAAATAGGAGATAAAAGCAACTTACGATA
TATTGAATTAACAATTATTATTCAGCAAGAAATGGTACCGTGGAATCATCCTCCCAAACA
AGAATTTATTTATGGAGAATGGTTACAAGAGCTTTATGAACAAGGATACATTCCTCAGAA
GGAATTAAATTCAGATTTAACCATAATGCTTTACCAAGCAAAACGAAAAAATAAAAGAAT
ATACGGAAATTATGACTTAGAGGAATTACTACCTGATATTCCATTTTCTGATGTGAGAAG
AGCCATTATGGATTCGTCAGAGGAATTAATAGATAATTATCAGGATGATGAAACCAACTC
TATATTAACTTTATGCCGTATGATTTTAACTATGGACACGGGTAAAATCATACCAAAAGA
TATTGCGGGAAATGCAGTGGCTGAATCTTCTCCATTAGAACATAGGGAGAGAATTTTGTT
AGCAGTTCGTAGTTATCTTGGAGAGAATATTGAATGGACTAATGAAAATGTAAATTTAAC
TATAAACTATTTAAATAACAGATTAAAAAAATTATAAAAAAATTGAAAAAATGGTGGAAA
CACTTTTTTCAATTTTTTTGTTTTATTATTTAATATTTGGGAAATATTCATTCTAATTGG
TAATCAGATTTTAGAAAACAATAAACCCTTGCATAGGGGGATCATCCGTTTAGGCTGGGC
GGTGATAGCTTCTCGTTCAGGCAGTACGCCTCTTTTCTTTTCCAGACCTGAGGGAGGCGG
CTCGAGACTAGTAAGATTATGATCTTCTGAACGACGAAAACTCGATTGAAAATATTGTAG
ATCAAATTGCTTCAGTTATTCATGATAATCAAAAAAAGTGAATCTCAGTCGAGATTCACT
TTTTCTTTAAAATAAAAAATCCGCCGCACCGAATGCAACGGACAAAACAATCTCCAATAT
ATGCTTGTGTTTCATTAGAATTAAAATCAATAACCGGTTGGCGGAAACGTGGGGAATCTA
ACCCCACTGAACGGATTTAGAGTCCATTCGATCTACATGATCACGTTTCCCCTAGGGTAT
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CGACAAGACTAACTATATCACGTATGTTCTCGTGTGGTCAAGCATTTTTAAAAACTTTTT
TTGTTTTTATGAAAATGCCGTGTTTACATAAGCAAAAAGGCGCACCTTGTCAGGCACGCC
TTTCCATAATTTACGGTTTCATTACTTCTCTATTCCCCATATAAGGACGAAGCACTTTCG
GAATCACAACGCTTCCGGCCGGCCAAAGCGTTGATTTGGGTAGTATGCTTTGACACAACA
AATTTTAATTTAGCAAATTCGATAGTCAACTCATTCTTAAGACCTAAATTAATGTTATTT
TTTAATAATTTACACCAAATTAATAGCAAAAATTATGTTATTCGTGCTAATATTTCATAG
TTGGTTATTCAATTAATTAAAAATAAGTCAAAATGCACAACTTTTTATAATTCATTGAGT
CGAGTTTGAAAAATAAAAGTGCTTTAATGCATGATCAATTATCGTACTTTCTATTATTTG
TTACCCGTTATCAATCGGAATAACGTATAGACACTTTAACGTGCTATAGATTGGTTTTAA
TCACTAAATTAATGTGTTTTTCTTATCATTAAAACTGCACTGAGAATTACTAAATTAAAA
AAATTATAAAAATTTTTCATTTTTAGTGATAAAATTCTGAAAAATGGGTATAAATAGTAG
AAGAAGTTAACTTGGAAGAGTTAAGCTATAACAAAGAATCTCTTTAGACACACATTGAAT
ATCGAAACATTTAATTGCGCTAAATCGTTTCATTAAATAAATTACCTTGTATTGTCGATT
AAATTAAGGTAAATTATAAAAAATGCTGATATTTTTGACTAAACCAAATGCTAACCCAGA
AATACAATCACTGTGTCTAATGAATAATTTGTTTTATAAACACTTTTTTGTTTACTTCTC
ATTTTTAATTAGTTATAATTAACTAAATAATAGAGCATTAAATATATTTAATAAAACTTA
TTTAATGCAAAATTATGACTAACATATCTATAATAAATAAAGATTAGATATCAATATATT
ATCGGGCAAATGTATCGAGCAAGATGCATCAAATAGGGAGGTTTTAAACTCTAGAATGGA
TAAAAAACCTCTTGACGTTCTTATCTCTGCTACAGGCCTTTGGATGTCTCGTACAGGCAC
ACTTCATAAAATCAAACATTACGAAATCTCTCGTTCTAAAATCTACATCGAAATGGCTTG
CGGCGATCATCTTGTTGTTAACAACTCTCGTTCTTGCCGTCCTGCTCGTGCTTTCCGTTA
CCATAAATACCGTAAAACATGCAAACGTTGCCGTGTTTCTGGCGAAGATATCAACAACTT
CCTTACACGTTCTACAGAAGGCAAAACATCTGTTAAAGTTAAAGTTGTTTCTGAACCTAA
AGTTAAAAAAGCTATGCCTAAATCTGTTTCTCGTGCTCCTAAACCTCTTGAAAACCCTGT
TTCTGCTAAAGCTTCTACAGATACATCTCGTTCTGTTCCTTCTCCTGCTAAATCTACACC
TAACTCTCCTGTTCCTACATCTGCTTCTGCTCCTGCTCTTACAAAATCTCAAACAGATCG
TCTTGAAGTTCTTCTTAACCCTAAAGATGAAATCTCTCTTAACTCTGGCAAACCTTTCCG
TGAACTTGAATCTGAACTTCTTTCTCGTCGTAAAAAAGATCTTCAACAAATCTACGCTGA
AGAACGTGAAAACTACCTTGGCAAACTTGAACGTGAAATCACACGTTTCTTCGTTGATCG
TGGCTTCCTTGAAATCAAATCTCCTATCCTTATCCCTCTTGAATACATCGAACGTATGGG
CATCGATAACGATACAGAACTTTCTAAACAAATCTTCCGTGTTGATAAAAACTTCTGCCT
TCGTCCTATGATGGCTCCTAACATCTTCAACTACGCTCGTAAACTTGATCGTGCTCTTCC
TGATCCTATCAAAATCTTCGAAATCGGCCCTTGCTACCGTAAAGAATCTGATGGCAAAGA
ACATCTTGAAGAATTCACAATGCTTAACTTCTTCCAAATGGGCTCTGGCTGCACACGTGA
AAACCTTGAATCTATCATCACAGATTTCCTTAACCATCTTGGCATCGATTTCAAAATCGT
TGGCGATTCTTGCATGGTTTACGGCGATACACTTGATGTTATGCATGGCGATCTTGAACT
TTCTTCTGCTGTTGTTGGCCCTATCCCTCTTGATCGTGAATGGGGCATCGATAAACCTTG
GATCGGCGCTGGCTTCGGCCTTGAACGTCTTCTTAAAGTTAAACATGATTTCAAAAACAT
CAAACGTGCTGCTCGTTCTGAATCTTACTACAACGGCATCTCTACAAACCTTTAAGCGGC
CGCATCACTGAAGCAAACAACGAAATTGAACTATAATTTTGTTTAGCGCAATTTGGTGAA
GTTTGATAGATGATACATTCTATTAAACTTCCTTTTTTTATGCTCTTTTTACCTAATTGT
TAAGAGGTTTTGCACTAATGGCACTCTGCAGCTCGAGAATGGTGTGAGGTTCCCGGGGAA
AAGCCAAATAGGCGATCGCGGGAGTGCTTTATTTGAAGATCAGGCTATCACTGCGGTCAA
TAGATTTCACAATGTGATGGCTGGACAGCCTGAGGAACTCTCGAACCCGAATGGAAACAA
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CCAGATATTTATGAATCAGCGCGGCTCACATGGCGTTGTGCTGGCAAATGCAGGTTCATC
CTCTGTCTCTATCAATACGGCAACAAAATTGCCTGATGGCAGGTATGACAATAAAGCTGG
AGCGGGTTCATTTCAAGTGAACGATGGTAAACTGACAGGCACGATCAATGCCAGGTCTGT
AGCTGTGCTTTATCCTGATGATATTGCAAAAGCGCCTCATGTTTTCCTTGAGAATTACAA
AACAGGTGTAACACATTCTTTCAATGATCAACTGACGATTACCTTGCGTGCAGATGCGAA
TACAACAAAAGCCGTTTATCAAATCAATAATGGACCAGACGACAGGCGTTTAAGGATGGA
GATCAATTCACAATCGGAAAAGGAGATCCAATTTGGCAAAACATACACCATCATGTTAAA
AGGAACGAACAGTGATGGTGTAACGAGGACCGAGAAATACAGTTTTGTTAAAAGAGATCC
AGCGTCGGCCAAAACCATCGGCTATCAAAATCCGAATCATTGGAGCCAGGTAAATGCTTA
TATCTATAAACATGATGGGAGCCGAGTAATTGAATTGACCGGATCTTGGCCTGGAAAACC
AATGACTAAAAATGCAGACGGAATTTACACGCTGACGCTGCCTGCGGACACGGATACAAC
CAACGCAAAAGTGATTTTTAATAATGGCAGCGCCCAAGTGCCCGGTCAGAATCAGCCTGG
CTTTGATTACGTGCTAAATGGTTTATATAATGACTCGGGCTTAAGCGGTTCTCTTCCCCA
TTGAGGGCAAGGCTAGACGGGACTTACCGAAAGAAACCATCAATGATGGTTTCTTTTTTG
TTCATAAATCAGACAAAACTTTTCTCTTGCAAAAGTTTGTGAAGTGTTGCACAATATAAA
TGTGAAATACTTCACAAACAAAAAGACATCAAAGAGAAACATACCCTGCAAGGATGCTGA
TATTGTCTGCATTTGCGCCGGAGCAAACCAAAAACCTGGTGAGACACGCCTTGAATTAGT
AGAAAAGAACTTGAAGATTTTCAAAGGCATCGTTAGTGAAGTCATGGCGAGCGGATTTGA
CGGCATTTTCTTAGTCGCGACGCGAGGCTGGATGGCCTTCCCCATTATGATTCTTCTCGC
TTCCGGCGGCATCGGGATGCCCGCGTTGCAGGCCATGCTGTCCAGGCAGGTAGATGACGA
CCATCAGGGACAGCTTCAAGGATCGCTCGCGGCTCTTACCAGCCTAACTTCGATCACTGG
ACCGCTGATCGTCACGGCGATTTATGCCGCCTCGGCGAGCACATGGAACGGGTTGGCATG
GATTGTAGGCGCCGCCCTATACCTTGTCTGCCTCCCCGCGTTGCGTCGCGGTGCATGGAG
CCGGGCCACCTACTGAAGTGGATTTCTTTAAGAGCTCCTTTAACTTCCTCACCAGTAGTT
GTATCGGTACCATAAGTAGAAGCAGCAACCCAAGTAGCTTTACCAGCATCCGGTTCAACC
AGCATAGTAAGAATCTTACTGGACATCGGCAGTTCTTCGAACAGTGCGCCAACTACCAGC
TCTTTCTGCAGTTCATTCAGGGCACCGGAGAACCTGCGTGCAATCCATCTTGTTCAATCA
TGCGAAACGATCCTCATCCTGTCTCTTGATCCATGGATTACGCGTTAACCCGGGCCCGCG
GATGCATATGATCAGATCTTAAGGCCTAGGTCTAGAGTCTTTGTTTTGACGCCATTAGCG
TACGTAACAATCCTCGTTAAAGGACAAGGACCTGAGCGGAAGTGTATCGTACAGTAGACG
GAGTATACTAGTATAGTCTATAGTCCGTGGAATTATTATATTTATCTCCGACGATATTCT
CATCAGTGAAATCCAGCTGGAGTTCTTTAGCAAATTTTTTTATTAGCTGAACTTAGTATT
AGTGGCCATACTCCTCCAATCCAAAGCTATTTAGAAAGATTACTATATCCTCAAACAGGC
GGTAACCGGCCTCTTCATCGGGAATGCGCGCGACCTTCAGCATCGCCGGCATGTCCCCCT
GGCGGACGGGAAGTATCCAGCTCGAGGTCGGGCCGCGTTGCTGGCGTTTTTCCATAGGCT
CCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGAC
AGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCC
GACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTC
TCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTG
TGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGA
GTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAG
CAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTA
CACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAG
AGTTGATAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTG
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CAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTAC
GGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATC
AAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAG
TATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTC
AGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTAC
GATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTC
ACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGG
TCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAG
TAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGTC
ACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTAC
ATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAG
AAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTAC
TGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTG
AGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAACACGGGATAATACCGC
GCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACT
CTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTG
ATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAA
TGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTT
TCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATG
TATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGA
CGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCC
CTTTCGTCTTCAAGAATT

(Sp)GFP (reverse strand, 720 bp)
TTATTTATACAATTCATCCATACCATGTGTAATACCAGCAGCTGTAACAAATTCCAACAA
AACCATGTGATCACGTTTTTCATTTGGATCTTTAGACAATTTAGATTGTGTAGACAAATA
ATGATTATCTGGCAACAAAACTGGACCATCACCAATTGGTGTATTTTGTTGATAATGATC
AGCCAATTGAACAGAACCATCTTCAATATTATGACGAATTTTAAAATTAACTTTAATACC
GTTCTTTTGTTTATCAGCCATGATATAAACATTATGAGAATTATAATTATATTCCAATTT
ATGACCCAAGATATTACCATCTTCTTTAAAATCGATACCCTTCAATTCGATACGATTAAC
CAATGTATCACCTTCAAACTTAACCTCAGCACGTGTCTTATAATTACCATCATCCTTGAA
AAAGATTGTACGTTCTTGAACATAACCTTCTGGCATAGCAGATTTAAAGAAATCATGTTG
TTTCATGTGATCTGGATAACGAGCAAAACATTGCAAACCATAAGCAAATGTTGTAACCAA
TGTTGGCCAAGGAACTGGCAATTTACCAGTTGTACAAATAAATTTCAATGTCAATTTACC
GTATGTAGCATCACCTTCACCTTCACCAGAAACAGAAAATTTATGACCATTAACATCACC
ATCCAATTCAACCAAAATTGGAACAACACCTGTAAACAATTCTTCACCTTTAGAAACCAT
*Bold underlined codons (AGA and TTC) indicate the residues that were mutated to
become TAG codons. AGA: S3, TTC: E18.

Complete orthogonal translation system (2797 bp)
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CTCGAGACTAGTAAGATTATGATCTTCTGAACGACGAAAACTCGATTGAAAATATTGTAG
ATCAAATTGCTTCAGTTATTCATGATAATCAAAAAAAGTGAATCTCAGTCGAGATTCACT
TTTTCTTTAAAATAAAAAATCCGCCGCACCGAATGCAACGGACAAAACAATCTCCAATAT
ATGCTTGTGTTTCATTAGAATTAAAATCAATAACCGGTTGGCGGAAACGTGGGGAATCTA
ACCCCACTGAACGGATTTAGAGTCCATTCGATCTACATGATCACGTTTCCCCTAGGGTAT
CGACAAGACTAACTATATCACGTATGTTCTCGTGTGGTCAAGCATTTTTAAAAACTTTTT
TTGTTTTTATGAAAATGCCGTGTTTACATAAGCAAAAAGGCGCACCTTGTCAGGCACGCC
TTTCCATAATTTACGGTTTCATTACTTCTCTATTCCCCATATAAGGACGAAGCACTTTCG
GAATCACAACGCTTCCGGCCGGCCAAAGCGTTGATTTGGGTAGTATGCTTTGACACAACA
AATTTTAATTTAGCAAATTCGATAGTCAACTCATTCTTAAGACCTAAATTAATGTTATTT
TTTAATAATTTACACCAAATTAATAGCAAAAATTATGTTATTCGTGCTAATATTTCATAG
TTGGTTATTCAATTAATTAAAAATAAGTCAAAATGCACAACTTTTTATAATTCATTGAGT
CGAGTTTGAAAAATAAAAGTGCTTTAATGCATGATCAATTATCGTACTTTCTATTATTTG
TTACCCGTTATCAATCGGAATAACGTATAGACACTTTAACGTGCTATAGATTGGTTTTAA
TCACTAAATTAATGTGTTTTTCTTATCATTAAAACTGCACTGAGAATTACTAAATTAAAA
AAATTATAAAAATTTTTCATTTTTAGTGATAAAATTCTGAAAAATGGGTATAAATAGTAG
AAGAAGTTAACTTGGAAGAGTTAAGCTATAACAAAGAATCTCTTTAGACACACATTGAAT
ATCGAAACATTTAATTGCGCTAAATCGTTTCATTAAATAAATTACCTTGTATTGTCGATT
AAATTAAGGTAAATTATAAAAAATGCTGATATTTTTGACTAAACCAAATGCTAACCCAGA
AATACAATCACTGTGTCTAATGAATAATTTGTTTTATAAACACTTTTTTGTTTACTTCTC
ATTTTTAATTAGTTATAATTAACTAAATAATAGAGCATTAAATATATTTAATAAAACTTA
TTTAATGCAAAATTATGACTAACATATCTATAATAAATAAAGATTAGATATCAATATATT
ATCGGGCAAATGTATCGAGCAAGATGCATCAAATAGGGAGGTTTTAAACTCTAGAATGGA
TAAAAAACCTCTTGACGTTCTTATCTCTGCTACAGGCCTTTGGATGTCTCGTACAGGCAC
ACTTCATAAAATCAAACATTACGAAATCTCTCGTTCTAAAATCTACATCGAAATGGCTTG
CGGCGATCATCTTGTTGTTAACAACTCTCGTTCTTGCCGTCCTGCTCGTGCTTTCCGTTA
CCATAAATACCGTAAAACATGCAAACGTTGCCGTGTTTCTGGCGAAGATATCAACAACTT
CCTTACACGTTCTACAGAAGGCAAAACATCTGTTAAAGTTAAAGTTGTTTCTGAACCTAA
AGTTAAAAAAGCTATGCCTAAATCTGTTTCTCGTGCTCCTAAACCTCTTGAAAACCCTGT
TTCTGCTAAAGCTTCTACAGATACATCTCGTTCTGTTCCTTCTCCTGCTAAATCTACACC
TAACTCTCCTGTTCCTACATCTGCTTCTGCTCCTGCTCTTACAAAATCTCAAACAGATCG
TCTTGAAGTTCTTCTTAACCCTAAAGATGAAATCTCTCTTAACTCTGGCAAACCTTTCCG
TGAACTTGAATCTGAACTTCTTTCTCGTCGTAAAAAAGATCTTCAACAAATCTACGCTGA
AGAACGTGAAAACTACCTTGGCAAACTTGAACGTGAAATCACACGTTTCTTCGTTGATCG
TGGCTTCCTTGAAATCAAATCTCCTATCCTTATCCCTCTTGAATACATCGAACGTATGGG
CATCGATAACGATACAGAACTTTCTAAACAAATCTTCCGTGTTGATAAAAACTTCTGCCT
TCGTCCTATGATGGCTCCTAACATCTTCAACTACGCTCGTAAACTTGATCGTGCTCTTCC
TGATCCTATCAAAATCTTCGAAATCGGCCCTTGCTACCGTAAAGAATCTGATGGCAAAGA
ACATCTTGAAGAATTCACAATGCTTAACTTCTTCCAAATGGGCTCTGGCTGCACACGTGA
AAACCTTGAATCTATCATCACAGATTTCCTTAACCATCTTGGCATCGATTTCAAAATCGT
TGGCGATTCTTGCATGGTTTACGGCGATACACTTGATGTTATGCATGGCGATCTTGAACT
TTCTTCTGCTGTTGTTGGCCCTATCCCTCTTGATCGTGAATGGGGCATCGATAAACCTTG
GATCGGCGCTGGCTTCGGCCTTGAACGTCTTCTTAAAGTTAAACATGATTTCAAAAACAT
CAAACGTGCTGCTCGTTCTGAATCTTACTACAACGGCATCTCTACAAACCTTTAAGCGGC
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CGCATCACTGAAGCAAACAACGAAATTGAACTATAATTTTGTTTAGCGCAATTTGGTGAA
GTTTGATAGATGATACATTCTATTAAACTTCCTTTTTTTATGCTCTTTTTACCTAATTGT
TAAGAGGTTTTGCACTAATGGCACTCTGCAGCTCGAG

SerT Promoter (within the OTS sequence; reverse strand, 200 bp)
GTATCGACAAGACTAACTATATCACGTATGTTCTCGTGTGGTCAAGCATTTTTAAAAACT
TTTTTTGTTTTTATGAAAATGCCGTGTTTACATAAGCAAAAAGGCGCACCTTGTCAGGCA
CGCCTTTCCATAATTTACGGTTTCATTACTTCTCTATTCCCCATATAAGGACGAAGCACT
TTCGGAATCACAACGCTTCC
SerT (within the OTS sequence; reverse strand, 72 bp)
TGGCGGAAACGTGGGGAATCTAACCCCACTGAACGGATTTAGAGTCCATTCGATCTACAT
GATCACGTTTCC)
SerT Terminator (within the OTS sequence; reverse strand, 200 bp)
AAGATTATGATCTTCTGAACGACGAAAACTCGATTGAAAATATTGTAGATCAAATTGCTT
CAGTTATTCATGATAATCAAAAAAAGTGAATCTCAGTCGAGATTCACTTTTTCTTTAAAA
TAAAAAATCCGCCGCACCGAATGCAACGGACAAAACAATCTCCAATATATGCTTGTGTTT
CATTAGAATTAAAATCAATA

sarA Promoter (within the OTS sequence; forward strand, 865 bp)
AAAGCGTTGATTTGGGTAGTATGCTTTGACACAACAAATTTTAATTTAGCAAATTCGATA
GTCAACTCATTCTTAAGACCTAAATTAATGTTATTTTTTAATAATTTACACCAAATTAAT
AGCAAAAATTATGTTATTCGTGCTAATATTTCATAGTTGGTTATTCAATTAATTAAAAAT
AAGTCAAAATGCACAACTTTTTATAATTCATTGAGTCGAGTTTGAAAAATAAAAGTGCTT
TAATGCATGATCAATTATCGTACTTTCTATTATTTGTTACCCGTTATCAATCGGAATAAC
GTATAGACACTTTAACGTGCTATAGATTGGTTTTAATCACTAAATTAATGTGTTTTTCTT
ATCATTAAAACTGCACTGAGAATTACTAAATTAAAAAAATTATAAAAATTTTTCATTTTT
AGTGATAAAATTCTGAAAAATGGGTATAAATAGTAGAAGAAGTTAACTTGGAAGAGTTAA
GCTATAACAAAGAATCTCTTTAGACACACATTGAATATCGAAACATTTAATTGCGCTAAA
TCGTTTCATTAAATAAATTACCTTGTATTGTCGATTAAATTAAGGTAAATTATAAAAAAT
GCTGATATTTTTGACTAAACCAAATGCTAACCCAGAAATACAATCACTGTGTCTAATGAA
TAATTTGTTTTATAAACACTTTTTTGTTTACTTCTCATTTTTAATTAGTTATAATTAACT
AAATAATAGAGCATTAAATATATTTAATAAAACTTATTTAATGCAAAATTATGACTAACA
TATCTATAATAAATAAAGATTAGATATCAATATATTATCGGGCAAATGTATCGAGCAAGA
TGCATCAAATAGGGAGGTTTTAAAC
sarA (within the OTS sequence; forward strand, 1260 bp)
ATGGATAAAAAACCTCTTGACGTTCTTATCTCTGCTACAGGCCTTTGGATGTCTCGTACA
GGCACACTTCATAAAATCAAACATTACGAAATCTCTCGTTCTAAAATCTACATCGAAATG
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GCTTGCGGCGATCATCTTGTTGTTAACAACTCTCGTTCTTGCCGTCCTGCTCGTGCTTTC
CGTTACCATAAATACCGTAAAACATGCAAACGTTGCCGTGTTTCTGGCGAAGATATCAAC
AACTTCCTTACACGTTCTACAGAAGGCAAAACATCTGTTAAAGTTAAAGTTGTTTCTGAA
CCTAAAGTTAAAAAAGCTATGCCTAAATCTGTTTCTCGTGCTCCTAAACCTCTTGAAAAC
CCTGTTTCTGCTAAAGCTTCTACAGATACATCTCGTTCTGTTCCTTCTCCTGCTAAATCT
ACACCTAACTCTCCTGTTCCTACATCTGCTTCTGCTCCTGCTCTTACAAAATCTCAAACA
GATCGTCTTGAAGTTCTTCTTAACCCTAAAGATGAAATCTCTCTTAACTCTGGCAAACCT
TTCCGTGAACTTGAATCTGAACTTCTTTCTCGTCGTAAAAAAGATCTTCAACAAATCTAC
GCTGAAGAACGTGAAAACTACCTTGGCAAACTTGAACGTGAAATCACACGTTTCTTCGTT
GATCGTGGCTTCCTTGAAATCAAATCTCCTATCCTTATCCCTCTTGAATACATCGAACGT
ATGGGCATCGATAACGATACAGAACTTTCTAAACAAATCTTCCGTGTTGATAAAAACTTC
TGCCTTCGTCCTATGATGGCTCCTAACATCTTCAACTACGCTCGTAAACTTGATCGTGCT
CTTCCTGATCCTATCAAAATCTTCGAAATCGGCCCTTGCTACCGTAAAGAATCTGATGGC
AAAGAACATCTTGAAGAATTCACAATGCTTAACTTCTTCCAAATGGGCTCTGGCTGCACA
CGTGAAAACCTTGAATCTATCATCACAGATTTCCTTAACCATCTTGGCATCGATTTCAAA
ATCGTTGGCGATTCTTGCATGGTTTACGGCGATACACTTGATGTTATGCATGGCGATCTT
GAACTTTCTTCTGCTGTTGTTGGCCCTATCCCTCTTGATCGTGAATGGGGCATCGATAAA
CCTTGGATCGGCGCTGGCTTCGGCCTTGAACGTCTTCTTAAAGTTAAACATGATTTCAAA
AACATCAAACGTGCTGCTCGTTCTGAATCTTACTACAACGGCATCTCTACAAACCTTTAA
sarA (within the OTS sequence; forward strand, 141 bp)
TCACTGAAGCAAACAACGAAATTGAACTATAATTTTGTTTAGCGCAATTTGGTGAAGTTT
GATAGATGATACATTCTATTAAACTTCCTTTTTTTATGCTCTTTTTACCTAATTGTTAAG
AGGTTTTGCACTAATGGCACT
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